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Prostate cancer (PCa) is a common malignancy being the second 
most diagnosed cancer and sixth leading cause of male cancer death 
worldwide. PCa may present itself in several ways; slow growing and 
relatively benign, or fast growing and metastatic. There is currently no easy 
way of determining which form is present. There are two major issues with 
the detection of PCa; the lack of a non-invasive diagnostic biomarker, and 
difficulty in determining the prognosis. The transforming growth factor 
beta (TGF-β) superfamily is comprised of 30 proteins with strong 
regulatory effects on growth, differentiation and apoptosis, including TGF-
β, activin and inhibin, and the bone morphogenic protein (BMP) and are 
associated with signalling through the SMA genes and mothers against 
decapentaplegic (SMAD) signalling proteins. This project aims to examine 
expression of the TGF-β superfamily and associated signalling pathways in 
human prostate cancer tissue to determine the potential role of TGF-β 
superfamily signalling in prostate cancer development. Gene expression 
was investigated using TGF-β focussed arrays, followed by validation with 
Western blotting in tissue samples from patients with low and high grade 
tumours to determine which signalling pathways were being utilized. The 
gene arrays showed significant alterations of several key genes between the 
low and high grade tumours. A two-fold increase of activin A and BMP3 
and down regulation of BMP7 was observed. SMAD3 activity appeared to 
have decreased indicating increased non-canonical activin A signalling, as 
well as an up-regulation of metastasis related genes Plasminogen 
urokinase A, GSC and a down regulation of the growth inhibitory gene 
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HIPK2. Western blot validation showed a statistically significant decrease 
in SMAD3 activation and SMAD4 content in high grade tumour tissue 
compared to low grade tumour tissue. This possible reduction in SMAD3 
activation and SMAD4 content is consistent with the literature, showing 
that the progression of prostate cancer is associated with these changes. 
This study therefore suggests that decreased canonical signalling may play 
a role in prostate cancer development, although this study is unable to find 
a reason for this reduction and the direct cause it may have in prostate 
cancer progression. This finding highlights the potential for future study 
on SMAD3 and SMAD4 in relation to prostate cancer development. 
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1 Introduction 
Prostate cancer is the 2nd most diagnosed cancer in men, with a 
higher incidence in developed parts of the world. It is the 6th leading cause 
of cancer related death in males worldwide (1). The diagnosis of prostate 
cancer is dependent on the use of prostate specific antigen (PSA), digital 
rectal examination and prostate biopsy. An issue with prostate cancer is 
not the diagnosis of prostate cancer but determining the prognosis. 
Prostate cancer can be either slow growing, where one will die from age 
before the disease, or aggressive and metastatic (2). Determining the path 
which prostate cancer may take is one of the main focuses of prostate 
cancer research. 
The Transforming growth factor beta (TGF-β) superfamily is a 
large group of 30 proteins that have strong associations with tissue 
development and tissue maintenance (3). They are strongly implicated in 
embryonic development early on, with functions such as mesoderm 
patterning and cell migration (4, 5). In mature tissue this superfamily of 
proteins are implicated in cell cycle control with associations with 
functions such as apoptosis and cell cycle arrest. The many ligands of the 
TGF-β superfamily share many of the same intracellular signalling 
molecules, such as the SMA genes and mothers against decapentaplegic 
(SMAD) molecules, that form the canonical pathway (6). Apart from this 
canonical pathway, the TGF-β superfamily may also signal through non-
canonical signalling molecules (7). This superfamily of proteins due to their 
association with cell cycle control have been implicated in both the 
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development and inhibition of various cancers, therefore becoming the 
point of focus of cancer research especially prostate cancer (8, 9, 10).  
The TGF-β superfamily is often associated with having dual roles 
in cancer. They have been shown to inhibit the progression of cancer by 
preventing the tumour from developing invasive qualities and inducing 
apoptosis. The TGF-β superfamily conversely has been shown to promote 
the development of cancer by promoting invasive qualities through 
epithelial-mesenchymal transition (EMT), and loss of cell adhesion (11). 
This duality of possible roles in cancer progression may be related to the 
normal roles that members of the TGF-β superfamily may have. Cancer is 
often referred to as a hijacking of normal biological function. The roles that 
the TGF-β superfamily have in cancer development can therefore be 
associated with a high jacking of TGF-β function, causing a shift from the 
tissue maintenance function that they have in mature tissue, and instead 
taking on roles similar to those seen in embryo development (12, 13, 14).     
This study aims to examine the relationship between the TGF-β 
superfamily signalling and the progression of prostate cancer. Due to the 
close similarity between ligand structure and signalling pathways, this 
study hypothesises that the progression of prostate cancer is linked to 
altered TGF-β superfamily expression and signalling (8). 
To test this hypothesis, this study uses a TGF-β focussed Real time 
quantitative polymerase chain reaction (RT-qPCR) array to test the bulk 
genomic expression of TGF-β superfamily related genes, comparing the 
expression between low grade prostate cancer tissues to high grade 
prostate cancer. Gene expression is then validated by the use of Western 
blot. 
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2. Literature Review 
 
2.1. Prostate cancer 
The prostate is an accessory sex organ that develops from the 
endodermal urogenital sinus in close association with the urethra. The 
prostate’s function is to secrete various nutrients and components of semen 
which are essential in fertility, this secretion comprises 30% of the semen 
volume during ejaculation. Structurally the prostate is comprised of many 
ducts that arise from the urethra in a branching fashion. These are often 
separated into four zones; the peripheral zone, central zone, transitional 
zone and the anterior fibromuscular stroma. In the commonly studied rat 
and mouse models the prostate is organised into distinct lobes. However in 
humans these lobes are not distinguishable to the naked eye.  The clinical 
significance of the human prostate structure is that different pathologies 
are often found in different zones (15, 16). The prostate is one of the most 
studied accessory sex glands. It is a common site of various pathologies 
such as inflammation, benign prostatic hyperplasia (BPH) in the transition 
zone, and the focus of this review prostate cancer (PCa), which is more 
common in the peripheral zone (17). Prostate cancer is the 2nd most 
diagnosed cancer in men, with a higher incidence in developed parts of the 
world. It is the 6th leading cause of cancer related death in males worldwide. 
PCa has higher incidences in western countries with increasing cases in 
Asia and Central and Eastern Europe (18). The highest prevalence among 
developed nations is in Australia and New Zealand (1, 19). Major risk 
15 
factors include family history of the disease, ethnicity (20, 21), general 
health (22, 23, 24), and age. 
As with most cancers progression is not simply tied to tumour 
growth. Also required is the accumulation of characteristics that benefit its 
survival and metastasis such as immune evasion and ability to invade and 
adhere through mechanisms such as epithelial-mesenchymal transition 
(EMT) and the induction of angiogenesis. EMT is the process by which 
epithelial cells lose their polarity and gain the ability to invade, migrate 
and differentiate a process essential in development and wound healing (9, 
11, 25). Angiogenesis is the process by which new blood vessels are made, 
important for development, healing, and providing nutrients (26). These 
processes in their normal context, are beneficial and essential for normal 
development and function, but taken out of context can have severe and 
detrimental biological consequences. Through EMT the tumour can invade 
and spread and through angiogenesis the tumour is nourished whilst 
having access to the bloodstream to invade. Cancer has both been referred 
to as the “wound that does not heal” and as a “caricature of human 
biological functions”, as it hijacks normal biological functions (8). Prostate 
cancer is especially troublesome in that the disease exhibits two vastly 
different phenotypes, either slow growing or fast growing and metastatic. 
Currently there is no way to determine the ability of an early 
tumour’s ability to undergo metastasis. Management of low grade prostate 
cancer often consists of observing the growth of the disease with multiple 
testing, and continually evaluating the histology of repeated biopsies (27). 
Diagnosing the disease is usually dependent on a combination of digital 
rectal examination, PSA testing and a prostate biopsy. PSA is a frequently 
used prostate specific biomarker that is circulates in the blood. Though 
PSA is prostate specific it is not cancer specific (28). PSA levels may elevate 
due to multiple non-cancer related reasons, such as BPH, infection (29, 30), 
aging, or even lifestyle choices which may result in some degree of 
compression in that area such as cycling. PSA is falling out of favour as a 
diagnostic marker due to this lack of prostate cancer specificity (30, 31). The 
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current gold standard for diagnosing prostate cancer is the usage of 
prostate biopsy and accurate staging of the disease based on the structure 
of the observed cells, with the Gleason score (2). The Gleason scoring 
system examines the malignancy and stage of prostate cancer based on the 
histology of the tumour biopsy. This score is a compilation of the 
prevalence of the two most apparent Gleason patterns. Tumour 
malignancy is based on the patterns present with lower grades denoting 
the cells that have more normal and regular cell shape (Gleason pattern 1-
3) and higher grades denoting greater irregularity in cell morphology 
(Gleason pattern 4-5) (9). Obtaining prostate biopsies involves an invasive 
procedure and is dependent on the needle actually getting a part of the 
tumour for analysis. Therefore the biopsy itself is not infallible (32). Due to 
factors like these, prostate cancer has a high risk of over diagnosis and 
overtreatment (33).  
The treatment of aggressive metastatic cancer is problematic with 
two main therapies; the greatly invasive prostatectomy and androgen 
depravation therapy (ADT). Both of these treatments can affect quality of 
life. ADT is the common treatment for cancer that has spread beyond the 
prostate. ADT is only palliative, merely hindering the cancer development 
for a period of time till it progresses to an androgen insensitive form, 
which is a guaranteed death sentence. Hence there is a need for both better 
diagnostic tools and methods of treatments (34).  
For a long time members of the TGF-β superfamily have been 
implicated in cancer progression and have become a target in research in 
the hope of finding either a biomarker for the diagnosis and prognosis of 
the disease or a better understanding of how the disease progresses and a 
potential therapy (35, 36). Methods of determining TGF-β’s role in prostate 
cancer usually involves using cell models such as the Lymph node 
carcinoma of the prostate (LNCaP) cell line, which represents a low grade 
prostate cancer, DU145 which represents an intermediate form of the 
disease, and PC3 cell lines which represents a high grade form of the 
disease, these comprise the classical prostate cell lines. Though these cell 
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lines are derived from samples that have metastasized, the differing 
molecular properties, such as sensitivity to androgens, allow these cell lines 
to model differing severities of the disease (37). 
2.2. Transforming growth factor beta (TGF-β) 
super family 
The TGF-β superfamily is a family of thirty proteins that share 
similar structure and function. They are comprised of dimers which bind to 
a type II receptor, which then recruits and phosphorylates a type-I receptor 
(Figure 2.1). This activated receptor then activates intracellular signalling 
proteins, SMAD proteins, which translocate to the nucleus to alter gene 
transcription (38). SMADs comprise the canonical pathways of TGF-β 
signalling, however, ‘non-canonical’ pathways exists and include Akt, and 
MAPK. The aforementioned pathways are implicated in development, 
wound healing, differentiation and controlling the cell cycle (7, 39, 40, 41). 
Due to the pleiotropy of possible effects, their role in cancer development 
and progression is context dependent, and members of the superfamily 
have been shown to be both cancer suppressive, and cancer promoting at 
different stages of the disease (42). The TGF-β superfamily members are 
associated with cancer progression in advanced stages of the disease 
providing actions that allow the tumour to progress and invade, such as; 
EMT (9, 11), fibrosis, myofibrosis, angiogenesis (43), and osteoclast 
differentiation (44, 45). All these functions are normal functions for TGF-β, 
and are important in the correct context, but in cancer this aberrant 
expression worsens the condition, by allowing it to invade, or altering the 
microenvironment to favour its metastasis (46). An example of this 
includes plasminogen urokinase A (PLAU), which cleaves plasminogen 
allowing for mass migration of cells. This cleaving of plasminogen aids 
invasion in cancer, but when expressed normally allows for wound healing 
(47, 48, 49). Homeobox protein goosecoid (GSC) gene which is involved 
with the Spemann organiser and the migration of cells, is another 
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developmental gene targeted by TGF-β superfamily signalling that, when 
aberrantly expressed, aids the progression of cancer  (50). Expression of 
target genes of TGF-β superfamily signalling like GSC and PLAU have 
associations with both canonical, and non-canonical intracellular signalling 
pathways. TGF-β superfamily related proteins have been shown to be up-
regulated in cancer and hence may be used as diagnostic markers, or to 
elicit a method for disease progression (41). Due to the structural similarity 
between TGF-β superfamily members, receptors and their pathways, as 
well as the non-canonical pathways fully understanding TGF-β signalling 
is complex. This means the signalling pathway may be affected by 
competition, inhibition by other TGF-βs family proteins as well as the 
formation of heterodimeric dimers that have different functions (51, 52, 53). 



















SMAD proteins are the intracellular signalling molecules that 
comprise the canonical pathway of signalling within the TGF-β 
superfamily. In total there are eight SMADs sorted into three classes. These 
three classes are R-SMADS (receptor regulated SMADs), Co-SMAD 
(common mediated SMAD) and I-SMADs (inhibitory SMADs) (38). The 
general functions of these SMADs is that R-SMADs are activated by the 
receptor ligand complex and then bind to the Co-SMAD which translocate 
to the nucleus and begin transcription with I-SMADs being an inhibitory 
control of this pathway (54). SMADs have been shown to have diverse and 
varied effects and are the target of a multitude of ligands for a 
comparatively conserved set of intracellular molecules (Figure 2.1). Thus 
they are the subject of further study to understand their role in the control 
of the cell cycle and how they relate to the progression of various cancers. 
For example, inhibition of SMAD3 by Pituitary tumour-transforming 1 
protein (PTTG1) during prostate cancer results in increased proliferation of 
the prostate cancer PC3 cell line, while up-regulation of SMAD3 results in 
decreased proliferation of PC3 cells (55). SMAD2 another target of TGF-β 
signalling is also a critical mediator of TGF-β mediated apoptosis and is 
preferentially activated by competition by the protein NODAL (56, 57). 
Mutations in SMAD4 genes have been implicated in allowing cancer to 
progress (58), with some prostate cancers showing down-regulated 
SMAD4 expression associated with increased severity, and increased 
invasive potential of the tumour (59, 60). SMADs are the mediating 
pathway by which TGF-β signalling induces various apoptotic effects such 
as the induction of lipid phosphatase SHIP and DAP kinases (3, 57). SMAD 
ubiquitin regulatory factors (SMURF) proteins are regulatory genes that 
affect BMP and TGF-β signalling through targeting SMADs. They are 
activated by SMAD7, an I-SMAD, and have effects on both R-SMADs and 
I-SMADS. As well as targeting SMAD proteins they also have effects in 
regulating receptors by ubiquitination thus altering ligand binding and 
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signalling ability (61). TGF-β signalling may be modulated by miRNA 
resulting in differential effects. SMAD proteins are also possible targets for 
miRNA modulation, altering expression (62). Further control of SMAD 
signalling is by an ETS related gene (ERG), which increases the 
phosphorylative potential of SMAD3 thus increasing overall TGF-β 
canonical signalling (63). Another example of this is PLAU, which is not 
only activated by SMAD4, but also by other pathways such as nuclear 
factor kappa light chain enhancer of activated B cells (NFκB) (64). The 
multiple modes of activation highlights the context dependent nature of 
TGF-β and SMAD signalling with possible overlap and redundancy even 
at a target level. SMAD7, an inhibitory SMAD may also be activated by 
TGF-β signalling in a negative feedback mechanism and has been shown to 
be required for TGF-β induced apoptosis activating the p38 pathway. This 
pathway like many aspects of TGF-β superfamily member signalling may 
be modulated by additional molecules such as Transforming growth factor 
beta-activated kinase 1 (TAK1) and mitogen-activated protein kinase 
kinase 3 MKK3 (65). SMAD7 not only acts as an inhibitory SMAD but has 
also been shown to interact with phosphorylated p38. As mentioned 
previously TGF-β signalling is able to modulate other TGF-β and SMAD 
pathways (66). The inhibition of the canonical pathway by inhibitory 
SMADs, is often associated with non-canonical pathway signalling as both, 
a way of causing preference for the noncanonical signalling pathway, and 
as a negative feedback control mechanism (67).  This highlights the diverse 
effects SMADs have, and thus deregulation of SMAD signalling is likely to 
lead to pathological states. 
Next in this review about TGF-β superfamily related signalling in 
relation to prostate cancer, the superfamily members TGF-β, activin and 





   
Figure 2.1: Simplified diagram of the signalling pathways that the 
main members of TGF-β superfamily may employ. This diagram highlights the 
high number of ligands relative to the low number of receptors and signalling 
pathways.  The ligands bind to type II receptors which then recruit type I 
receptors via phosphorylation. Inhibitory family members are in red. Ligands 
shown are the main ligands covered by the TGF-β focussed RT-qPCR array used 



















































The main members of the TGF-β superfamily comprise of main 3 
isoforms TGF-β1, TGF-β2 and TGF-β3; that have 6-9 cysteine residues that 
form disulphide bonds between subunits. The isoforms normally bind to 
the TGF-β receptor 2 (TGFBR2), which then recruits the TGF-β type 1 
receptor (TGFBR1). This complex then acts on SMAD2/3 recruiting 
SMAD4 to result in gene transcription. TGF-β is secreted in vivo as a latent 
complex. These precursor molecules are then cleaved by the proprotein 
cleavage protein, Furin (Figure 2.2) (40) to release the mature/signalling 
portion. TGF-βs may bind to latent TGF-β binding proteins in order to 
prolong the half-life of the molecule as well as provide recognition sites to 
allow the activation of the molecules, showing tight regulation (67). 
However despite being associated with signalling through SMAD2/3, 
TGF-β has been known to also signal through SMAD1/5/8 pathways more 
associated with BMP signalling, through the activation of the BMP type-1 
































As mentioned before, TGF-β1-3 have tumour suppressive effects 
early in cancer development. TGF-βs have been shown to up-regulate Par 
4, a proapoptotic gene, through canonical pathways, this activation of Par 4 
inhibits EMT. Loss of the TGF-β receptor II, loss of SMAD4 signalling, 
results in TGF-β inactivation and leads to rapid development of invasive 
metastatic cancers (10). TGF-β can also induce apoptosis through SHIP 
proteins, DAP-kinases, and TIEG (Figure 2.3). An additional method of 
apoptosis induction is through cJUN-N-terminal kinase activation (JNK) 
activation (69). Alternative cancer suppressive targets of TGF-β signalling 
include p15 and p21 (11). TGF-β may stimulate the collective migration of 
cells through signalling through the ERK pathway. However, the knockout 
and inhibition of TGF-β signalling has also been shown to also induce 
cancerous phenotypes, showing the context dependent nature of TGF-β 
signalling in the promotion of cancer (Figure 2.4) (11). The pleiotropic role 
of TGF-β may be due to modulation of tumour suppressor, or promoter 
effects, or by other regulatory molecules, such as miRNAs, showing a 
variety (70, 71). Another possible cause for the context dependent nature of 
TGF-βs and their family members may be due to alterations in the tumour 
microenvironment (46). Microenvironment alterations may occur through 
multiple pathways for example, p15 and p21 are known tumour 
suppressors, or Snail family zinc finger 1 and 2 (SNAI1/SNAI2),  
myelocytomatosis viral oncogene homologue (c Myc), and DNA-binding 
protein inhibitor (Id) which are implicated in promoting the disease (70). 
Further tumour promoting effects of TGF-β include causing cells to 
differentiate to myofibroblasts which as secretory cells may secrete more 
factors leading to tumour development (72). Aggressive phenotypes 
caused by TGF-β expression may not include increased proliferation as 
shown with TGF-β3 which increases the invasive capabilities of PC3 cells 
but has no effect on proliferation (73).  
TGF-β also show tissue or cell dependent effects. This is especially 
shown with its effects on immune cells. The suppression of immunity is 
beneficial for cancer progression allowing it to evade the immune system. 
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TGF-β inhibits naive T cells from developing into CD4+ helper T cells or 
C8+ cytotoxic T cells through negative regulation of  GATA-binding factor 
3 (GATA-3) (9, 74). This is modulated by SRY-related HMG-box 4 (SOX4) 
transcription factors, showing that regulation may be modulated by 
additional factors. Effectiveness differs between isoforms with TGF-β3 
being the most effective in inducing invasive capabilities in PC3 cells, 
compared to TGF-β1 and TGF-β2, by activating the PI3-kinase pathway via 
SMAD3 (75). This isoform of TGF-β was found to be expressed at highest 
levels in PC3 cells and yet had no effect on proliferation of the PC3 cell line. 
It instead inhibited the proliferation of the prostate cancer cell line DU145 
(76). This highlights that there are additional mechanisms by which TGF-β 









Figure 2.3: Simplified diagram of TGF-β canonical signalling pathway. 
TGF-β binds to type-II receptor, which recruits type-I receptor via 
phosphorylation. TGF-β	   has	   the	   shared potential to activate a SMAD1/5/8 
pathway shared with BMP. Despite this potential to signal via SMAD1/5/8, the 
preferred pathway is via SMAD2/3. Shown are potential targets, these targets 
have diverse effects, such as controlling tissue maintenaince via induction of 




















































Figure 2.4: Simplified diagram of TGF-β  non-canonical pathway. 
Activation of the non-canonical pathway inhibits SMAD signalling. The same 
receptors are activated as in the canonical pathway, however, SMAD signalling 
is inhibited by SMAD7 allowing the further activation of the various 
components of non-canonical pathway. Also highlighted in the diagram is the 
multitude of possible effects that non-canonical signalling have both cancer 























































2.5. Activins and inhibins 
Other members of the TGF-β superfamily include the activins and 
inhibins. These proteins are composed of dimers of the inhibin subunits 
Activin is made up of inhibin β subunits which exist in 4 isoforms A, B, C, 
and E and may either exist in heterodimeric or homodimeric forms. Activin 
was named for its ability to stimulate follicle stimulating hormone (FSH). 
Inhibin is a molecule that inhibits activin signalling, and was discovered 
because of its ability to inhibit FSH signalling. Inhibins are again dimers 
comprised of an inhibin α subunit and either inhibinβ A or B subunit. The 
most common form of activin is activin A, encoded by the gene INHBA. 
Activins are structurally similar to TGF-βs in that they share 6-9 cysteine 
residues that form disulphide bonds. Their receptors are almost identical, 
with a total of 21 overlapping target genes. This structural similarity hints 
at redundancy in signalling, due to shared recruitment of SMAD2, SMAD3 
and SMAD4 (Figure 2.5).  The differing roles that TGF-β and activin have 
are hard to elicit postnatally, due to the aforementioned recruitment of 
SMAD2, and SMAD3 by both families, as well as non-canonical signalling 
(Figure 2.5, Figure 2.6) (8, 53, 77). Activin is also implicated in wound 
healing allowing for the fibrosis and scar formation, as well as cell renewal. 
Like TGF-β it has been shown to have roles in cancer. Activin A has been 
shown to be up-regulated in cancer and in a cachexia like wasting 
syndrome. Further possible evidence of activins’ role in cancer is that 
inhibin knockout mice develop stromal cord sex tumours with activin 
being found in supraphysiological levels in these mice (78, 79, 80). 
Metastasis to bone is also associated with activin A however in a different 
method to TGF-β and BMP in that it involves osteoclastic activity instead of 
osteoblastic activity (45, 81). Activin A has been shown to have many 
inhibitors, inhibin and follistatin being the main ones, while activin C has 
also been shown to be antagonistic towards activin A and B signalling (35, 
80). The activin C knockout has been shown to have no effect in increasing 
or decreasing prostate cancer induction. Up-regulation of activin C 
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however, has been shown to significantly decrease activin A signalling and 
the increase proliferation of prostate cancer cell line LNCaP (35, 82) and 
slows down the progression of prostate cancer (80). Cripto, a molecule that 
facilitates NODAL binding to ACVR1B has been shown to antagonise 
activin signalling. BAMBI and BMP3 have also been shown to antagonise 
activin signalling highlighting a structural similarity and possible 
redundancy between BMP and activin as both their receptors may be acted 
on by the antagonist (51, 83). Additional regulatory molecules that can 
control activin signalling are the presence of various miRNA, providing 
another possible avenue for future study (62). Activin is usually associated 
with growth inhibitory effects in normal physiology and has apoptotic 






Figure 2.5: Simplified diagram of canonical activin signalling. Activin 
A binds to type-II receptor ACVR2A, which recruits type-I receptor ACVR1. 
Activated receptor dimer then phosphorylates SMAD proteins which translocate 
to the nucleus to activate gene transcription. Possible results of canonical activin 
A signalling include controlling the cell cycle, controlling SMAD2/3 signalling 








































Figure 2.6: Simplified diagram of non-canonical activin signalling. 
Highlights the multiple non-canonical pathways that may be activated as well as 
interactions with each other and potential role cancer biology. Diagram 















































2.6. Bone morphogenetic protein (BMP) 
BMPs are comprised of 19 members. These ligands bind to 
BMPRII and BMPRI, signal through SMAD1, 5, and 8, (Figure 2.7) and are 
usually implicated in regulation of bone formation via osteoblast 
differentiation (86). Inhibitors of BMP function include BMP3, BMPER, 
NOGGIN, and BAMBI, a pseudo receptor that may bind other members of 
the TGF-β superfamily (87, 88). BMP3 is a unique member of the BMP 
family in that it is the only inhibitory BMP, fulfilling a role similar to how 
activin C inhibits activin A/B, in that BMP3 inhibits other isoforms of the 
BMP family. BMP3 competes for BMP receptors preventing signalling from 
occurring and may also inhibit activin A signalling (83). BMP3 is able to 
promote adipogenesis via activin A pathways, providing an example of 
both how the different SMAD pathways may interfere with each other, as 
well as the structural similarities between family members (89). BMP2 and 
BMP6 have been shown to increase tumour invasiveness (90, 91), 
conversely BMP7 and BMP4 have inhibitory effects on tumour 
invasiveness (92). This corresponds to studies that show that BMP7 is a 
negative growth regulator of cancer and is down-regulated in PCa, this 
highlights that there are possibly different mechanisms of actions within a 
TGF-β subfamily (93). BMP7 is a potent inhibitor of TGF-β induced EMT, 
counteracting SMAD3/4 activation as well as countering metastasis to 
bone in vivo (52).  Studies by Kwon et al (2014) suggested that BMP6 
secreted by the tumour may also have a role in altering the 
microenvironment, aiding invasiveness by up-regulating VEGF, a protein 
involved in angiogenesis (94). BMPs therefore may be a therapeutic target 
either by targeting cancer promoting BMP signalling, SMAD proteins, or 
restoration of normal BMP function. Studies on BMP have also highlighted 
the further complexity of TGF-β superfamily signalling. Heterodimers of 
BMP2/7 monomers have been shown to differentially target TGF-β 
signalling, to be more potent in the negative regulation of breast cancer and 
TGF-β directed SMAD signalling and be less susceptible to noggin 
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inhibition than BMP2 and BMP7 alone (52). This possible control highlights 
a possible avenue for future study and a mechanism for the alteration of 
ligand function, whilst also eliciting their specific role in prostate cancer. 
There is conflicting evidence about the effects of BMP2 and BMP4 on 
tumour growth and invasiveness which may be due to tissue type, further 
adding to signalling complexity.  BMP4 has been shown to induce EMT 
and Rho GTPase activation in human ovarian cancer cells, an overt 
increased invasive response was only seen in the cancerous ovarian cells 
and not the ovarian surface epithelium cell controls (25). BMP7 has also 
been shown to induce EMT and though down-regulated in prostate cancer 
is up-regulated in breast cancer (86, 93). Again this displays the context 
dependent nature of responses to TGF-β superfamily signalling (25). As 
mentioned previously, BMP3 can inhibit activin as well as other BMP 
signalling, providing an example of how the structural similarity of TGF-β 
superfamily members and the interrelations they may have (95).  
Often described as a sub group of the BMP family, the Growth 
and Differentiation factors (GDF) are comprised of 15 members. These 
ligands can also influence cancer development. GDF9 overexpression has 
been shown to increases in proliferation in PC3 cells through TGFBR1 
receptors (96, 97). GDF5 is a ligand induced in breast cancers, whereby the 
expression of TGF-β and GDF5 induces angiogenesis, as demonstrated in 
vivo and in vitro (43). GDF15, also referred as macrophage inhibiting 
cytokine, is a ligand that is up-regulated in cancer. This may be due to its 
association with stress, tissue damage and development whilst its role in 
cancer is not fully understood, as its knockout is not lethal and merely 
impairs immune evasion in utero. GDF15 has shown potential as a 
diagnostic biomarker when used in conjunction with PSA, as it increases 
the diagnostic accuracy of PSA in prostate cancer (98). The sensitivity of 
BMP signalling may be modulated by the expression of P53 and 
ΔNp63alpha, which can not only modulate BMP signalling, but also allow 
the induction of BMP signalling after TGF-β signalling. These targets have 
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been shown to have traits that benefit tumour development, and 
demonstrate the cross-talk between BMP and TGF-β	  (86). 
    
   
Figure 2.7: Simplified diagram of BMP signalling pathway showing 
both a canonical SMAD and non-canonical pathway. Canonical SMAD1/5/8 
pathway may inhibit TGF-β/activin related SMAD2/3 pathways. 
   





































NODAL is a member of the TGF-β family and also an activin 
antagonist. As with many other members of the TGF-β superfamily, 
NODAL has a multitude of functions in embryonic development and is 
essential in maintaining pluripotency and mesoderm patterning (99). 
Expression of NODAL is largely confined to embryonic development and 
stem cells, and is largely absent from adult tissue such as differentiated 
epithelia. NODAL, however is a promising target in cancer as NODAL and 
its receptors have been shown to be up-regulated in metastatic cancer 
progression. The expression of NODAL in vitro is associated with more 
aggressive prostate cancer cell lines DU145 and PC3, and when it is 
expressed in LNCaP cells they exhibit increased invasive abilities (14). 
NODAL homodimers, aided by the co-receptor Cripto, bind to ACTRIIB 
receptors which recruit ACVR1B/C, type 1 receptors hence competing 
with activin for providing competition for ACVR1B receptor binding, 
preferentially activating SMAD2. Though, like other TGF-βs, signalling has 
an additional layer of complexity with Cripto-independent mechanisms of 
signalling. Cripto-independent signalling has been shown to inhibit 
SMAD1 phosphorylation by BMP. Whether this inhibition of BMP occurs 
under normal expression of NODAL has not been determined as the 
physiological levels of NODAL have not been ascertained. However, 
heterodimers consisting of BMP7 and NODAL are also possible, due to the 
affinity for NODAL binding to BMP7 and BMP3 being as strong as it’s 
affinity for homodimerisation. These heterodimers do not activate either 
SMAD1 or SMAD2, though this has yet to be shown in vivo (56). NODAL 
signalling has been shown to be influential in other cancer types such as 
glioblastoma proliferation (13). NODAL has also presented itself as a 
possible target in pancreatic and gastric cancer. Additionally, NODAL 
signalling is antagonised by both the proteins; cerberus  and Lefty, which 
has been shown to supress NODAL signalling in breast cancer by binding 
directly to NODAL forming stable complexes, preventing receptor binding. 
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This inhibition of NODAL signalling suppresses the metastatic ability of 
NODAL expressing breast cancer cells, providing a possible target for the 
treatment of cancer (4). 
 
2.8. Research and models 
Prostate cancer research has been mainly carried out in three 
ways; using cell lines, animal models, and human tissue samples. The use 
of cell lines employs either immortalised cancer cell lines or immortalized 
primary cell cultures in in vitro experiments. The benefits of cell lines are 
the greater degree of control over external factors in vitro, and the ability to 
see dose dependent responses after an exposure. The results may be 
ascertained by either differences in growth, gene expression or protein 
expression, responses that may be directly attributed to the altered 
variable. In addition, in vitro experiments are relatively reproducible and 
cost effective. The main disadvantage of this experimental approach, 
however, is the difficulty to directly correlate the effects observed with 
possible functional outcomes in a full biological system such as the 
interaction with the microenvironment (100, 101, 102).  
Animal studies address this issue by adding a layer of complexity, 
providing a more accurate reflection of what may occur in a biological 
system. Animal studies of prostate cancer often involve the growth of a 
prostate cancer cell line that is then implanted into the test species, or by 
the utilisation of transgenic animals in knockdown or gene overexpression 
studies to induce tumours. The added layer of complexity more closely 
mimics the human condition and provides insight into how a disease may 
affect the system as a whole whilst allowing for a great degree in control of 
the experiment. However issues still exist due to interspecies differences 
between humans and the animal models that may not directly translate to 
the clinic (103). Another limitation of animal studies is that the condition 
studied in that model may not truly represent the natural condition. For 
example, knocking-down or up-regulation of a gene that results in an 
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extreme phenotype and the implantation of a tumour into an animal 
model, as opposed to the slow development of the disease observed in 
humans. These tumour implanted animals are either immune-deficient 
nude mice, or transgenic mice. Thus they may have symptoms not related 
to the tumour but stemming from other systemic effects, or express a gene 
or protein in such super biological levels or respond to a possible treatment 
in such a way that they are not fully representational of the disease 
clinically (104). Another issue with animal models is that these models 
develop the disease acutely and severely and often have a short life 
expectancy, again not fully representative of the disease in humans, who 
often develop the disease whilst aging. 
 Human studies are largely limited to cross-sectional 
epidemiological studies (18, 19) or the use of human tissue. Such studies 
are limited by a lack of controls compared to the amount of tumour tissue 
(105) and quite often lack the experimental freedom of other models such 
as the ability to directly test the response to a specific condition, being 
unable to directly add or knockdown genes to see their effect. Human 
studies generally are more useful due to having more data that may 
translate to clinical significance, providing an important insight to how the 











2.9. Summary of   TGF-­‐‑β   superfamily  
interactions  in  relation  to  prostate  cancer 
Most studies studying TGF-β superfamily involvement in cancer 
and its progression look at a few genes in isolation (79, 83, 93, 94). Whilst 
this is useful for teasing out how a gene and its protein may work, studies 
like these ignore the fact that due to the structural and functional 
similarities, there may be a lot of cross-talk or redundancy occurring 
between genes and their signalling pathways, especially considering that 
there exists more ligands than receptors(77). This has been demonstrated 
between specific members of the TGF-β superfamily with family members 
either able to antagonise one ligand’s ability to signal, altering its signalling 
by forming heterodimers (52) and in some instances they may compete for 
receptors and downstream signalling molecules, or may bind to another 
TGF-β superfamily ligand’s receptor. Apart from the modulatory effects 
that TGF-β superfamily members may have on the signalling of other TGF-
β superfamily members, TGF-β superfamily members have important 
effects on development in their pleiotropic repertoire (106). This 
complexity of signalling could possibly alter the effectiveness of TGF-β 
derived treatments (107). It is the hijacking of these functions that lead to 
the cancer promoting effects seen in cases of cancer. Hence what is 
required is that the interactions between TGF-β superfamily members and 
their common signalling pathways are quantified.  TGF-βs are implicated 
in the alteration of the tumour microenvironment and stroma, therefore 
benefiting the progression of the tumour and its ability to progress (101, 
102). Such alterations provide an environment beneficial for the tumour to 
progress to a state where it can metastasise and proliferate (108), functions 
that mirror their developmental effects such as; proliferation and EMT 
rather than the postnatal effects of cell cycle control. However the greatest 
hurdle to fully understanding TGF-β superfamily signalling is the 
interrelations they possess. With better understanding of the possible 
39 
interactions between TGF-β family members and their downstream effects, 
diagnostic and therapeutic agents specific to tumour type  may be 
developed, or in the very least narrow possible avenues to investigate.  
 
2.10. This project 
This project aims to examine the TGF-β related superfamily 
expression in prostate cancer. By looking at the gross expression of the 
superfamily we may be able to infer a mechanism for prostate cancer 
progression in relation to TGF-β related signalling. This study hypothesises 
that the expression of TGF-β superfamily members and related signalling is 
altered on a gross level, and it is this alteration that contributes to prostate 
cancer progression. This study aims to show this by showing possible 
patterns of altered regulation of TGF-β superfamily members and their 
signalling is possibly related to the more aggressive forms of prostate 
cancer. The importance of this study is the possible discovery of, or 
progression to, a TGF-β related biomarker in prostate cancer progression, a 




3.1. Human prostate samples 
 
100 human prostate samples were obtained from the Christchurch 
tissue bank (ethics number H15/004) preserved in Tissue Tek® O.C.T 
compound. These samples were derived from prostate biopsies from 
individuals ranging in age between 53 and 75. Samples were comprised of 
tissue with prostate cancer and also normal adjacent tissue. For each 
sample, information was provided concerning the Gleason score, pattern 
and other parameters such as presence of capsular invasion and necrosis. 
For this study, 24 samples from 12 patients (12 tumour tissue and 12 
matching normal adjacent tissue) were used and divided into three initial 
groups based on Gleason score. These groups initially were; low, Gleason 
score of less and equal to six, intermediate, Gleason score greater than six 
but less than eight, and high, Gleason score greater than eight. Each sample 
was divided in half for mRNA extraction and protein extraction. 
Subsequently, after clinical advice it was deemed that the intermediate 
group should be included with the high group due to Gleason patterns 






3.2. Total RNA extraction and cDNA 
conversion 
One half of each sample was homogenized in Trizol (1 mL per 50-
100 mg of tissue). The insoluble material was removed by centrifugation at 
12,000 g for 10 minutes at 2-8°C. The homogenate was incubated for 5 
minutes at 15-30°C to allow for the complete dissociation of nucleoprotein 
complexes. Chloroform, 200 μL for every mL of Trizol, was added to each 
sample and mixed and incubated at 15-30°C for 2-3 minutes to help 
separate less polar substrates from the polar nucleic acids. The resulting 
solution was then centrifuged at 10,600 g at 25°C for 15 minutes to separate 
the homogenate into an aqueous and organic phase. Qiagen’s RNeasy kit 
(CAT#74104 Qiagen) for mRNA purification was used for purification of 
the aqueous phase by centrifuging it with ethanol at 10,600 g in the 
RNAeasy spin column to force the nucleic acid to precipitate, followed by 
two revolutions at 10,600 g with “RPE Buffer” contained in RNeasy kit, to 
remove any contaminants and a final collection by centrifugation with 
RNAse free water was undertaken to collect the total RNA from the from 
the filter in the spin column. The concentration and purity of the total RNA 
yield was quantified with a Nanodrop spectrophotometer. Wavelengths of 
260 nm, 280 nm, and 230 nm were used, to detect nucleic acids, 
contaminates such as proteins, and contaminants such as guanidine 
respectively. 260/280 and 230/260 ratios of 2.0 and 2.0-2.2 respectively 
were accepted as being pure and free from contaminants that absorb at 280 
nm and 230nm. RNA was stored at -80°C prior to conversion to cDNA.  
Conversion to cDNA was performed with the Qiagen RT2 First 
Strand kit (CAT#330411 Qiagen). This involved heating 8 μL of RNA with 
6 μL the “GE Buffer” supplied in the RT2 First Strand kit, at 37°C for 5 
minutes, to remove genomic DNA. cDNA formation was done with an 
additional heating of the RNA sample with 6 μL of the reverse 
transcriptase and base primers in the “BC4 Reverse Transcriptase Mix” 
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supplied in RT2 First Strand kit. Final heating cycle consisted of heating at 
42°C for 15 minutes to allow the reverse transcription to occur, and 95°C for 
5 minutes to terminate the reaction.  
 
3.3. TGF-β focused gene array 
Qiagen RT2 PCR Array Human TGF-β/ BMP Signalling Pathway 
(CAT# PAHS-035ZA-24 Qiagen) was used to quantify TGF-β  superfamily 
related gene expression. For the PCR component, 1350 µL 2x RT2 SYBR® 
ROX Green mastermix (CAT#33623 Qiagen), 102 µL of the cDNA synthesis 
from each sample obtained prior and 1248 µL of RNase-free water. 25 µL of 
PCR component mix was added to each of the 96 wells, sealed and 
centrifuged at 100 x g to remove bubbles. The plates were then read on a 
Stratagene Mx3000p qPCR machine. Fluorescent dyes selected for 
measurement were SYBR and ROX, with ROX set as a reference dye.  The 
thermal profile cycle consisted of: 1 cycle of 95˚ C for 10 minutes for 
segment 1, 95˚C for 15 seconds and 60˚C for one minute with segment 2 for 
40 cycles, and segment 3 for the dissociation curve 1 cycle consisting of 
















3.4. TGF-β array analysis 
PCR analysis began after the run and consisted of setting 
amplification plots of the area to analyse and manually setting the baseline 
and threshold values in order to calculate the threshold cycle. The baseline 
was set from cycle number two to two cycle values before the earliest 
visible amplification in a linear view form. The threshold was set above the 
background noise and within the lower third of the linear phase of the 
amplification plot in Log view form.  This was repeated for each sample 
individually.  
Data analysis was done using Qiagen assisted data analysis at 
http://www.qiagen.com/nz/shop/genes-and-pathways/data-analysis-
center-overview-page based on details by Arikawa et al (2011) (109, 110) 
and selecting for the RT-qPCR machine and array kit used. Cycle threshold 
data were analysed by selecting the geometric mean and normalized 
manually by selecting the housekeeping gene with the lowest coefficient of 
variation, determined by sample standard deviation divided by the sample 
mean. Groups tested were; normal adjacent tissue to matched tumour 
group, normal adjacent tissue low versus high, and tumour tissue low 
versus high.  
Each group (including the control) included at least 3 samples for 
the software to calculate p-values (111). Fold-expression was normalised to 
one of 6 housekeeping genes, ACTB, B2M, GAPDH, HPRT1 and RPLP0, 
the house keeping gene with the lowest coefficient of variation calculated 
by dividing standard deviation by the mean.  Data were exported to 
Microsoft Excel and standard error of the mean was calculated from 
average fold change. Genes with biologically significant expression (two 
fold up or down-regulation) were compiled and graphed with Graphpad 
Prism with standard error of the mean (SEM). Comparisons made for the 
final study were between high grade prostate cancer tumour tissue 
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compared to low grade prostate cancer tumour tissue as it was found that 
normal adjacent tissue was too variable to use as a control. 
 
3.5. Protein extraction 
Remaining tissue was weighed and homogenised with RIPA 
buffer (CAT#R0278 Sigma-Aldrich®) at concentrations of 500 µL per 50-70 
mg of tissue. Thermo HALT Protease and Phosphatase Inhibitor Cocktail 
(CAT#1861281 Thermo Fisher Scientific®) were added at concentrations of 
1/100 per volume of RIPA buffer to inhibit protease and phosphatase 
activity. The samples were kept on ice for 20 minutes then sonicated for 5 
minutes in a bath sonicator. Samples were centrifuged at 16,100 g at 4°C, 
with the resulting supernatant being isolated for future use. Protein 
concentration was determined by bovine serum albumin (BSA) assay. 
Samples were kept at -80°C prior to usage. 
 
3.6. BSA Assay 
 Protein concentration of samples were determined using a bovine 
serum albumin (BSA) assay (CAT#23227 Thermo Fisher Scientific®). 
Standards were prepared by diluting BSA with RIPA buffer to provide 
concentrations of 2 mg/mL, 1.5 mg/mL, 1 mg/mL, 0.75 mg/mL, 0.5 
mg/mL, 0.25 mg/mL, 0.125 mg/mL, 0.025 mg/mL and a zero control. All 
standards and samples were loaded in triplicate. Standard solutions were 
loaded in aliquots of 25 μL, with 200 μL of working reagent. Samples were 
loaded in volumes of 2.5 μL to provide a 1/10 dilution with RIPA buffer to 
prevent an overload reading. Plates were incubated at 37°C for 30 minutes, 
Concentrations were determined using Gen 51.11 software on a Biotek® 





3.7. Western Blots 
Western blot analysis was used to determine the presence and 
relative levels of the following proteins; inhibin beta alpha, phosphorylated 
ERK1 and ERK2, SMAD4, SMAD1, SMAD3, phosphorylated SMAD1, 
phosphorylated SMAD3, BMP3, and BMP7 with GAPDH as a loading 
control. Gels consisted of a 12% separating gel and a 4% stacking gel. The 
total volume of sample per well was 20 μL with 1X Laemmli sample buffer 
(recipe in Appendix 1), this comprised of 30 μg of protein and double 
distilled H2O to bring the final volume to 10 μL with an additional 10 μL of 
2X Laemmli sample buffer with Dithiothreitol (DTT) to make up the 
required volume. If the protein concentration of the sample was low i.e. not 
able to load 30 μg within at most 10 μL, 15 μL of sample was used with 5 
μL of 4X Laemmli sample buffer with DTT. A loading control of 20 μL of 
1X Laemmli sample buffer was also used. Prior to loading samples were 
boiled at 98°C for five minutes then left to cool at room temperature for an 
additional five minutes. Along with the samples 3 μL of rainbow marker 
(CAT#RPN800E Amersham) was loaded in a dedicated well and a blank 
control of 10 μL of 2X Laemmli sample buffer without DTT and 10 μL of 
double distilled water in a dedicated well . Gels with samples were run in 
1X running buffer at a constant 120 V for 2 hours at 4°C. Next, gels were 
removed from the plates and transferred to 1X transfer buffer to equilibrate 
for ten minutes at room temperature with gentle shaking. Gels were 
transferred in 1X transfer buffer onto a nitrocellulose membrane 
(CAT#10600003 Sigma Aldrich®) at a constant 90 V for 70 minutes at 4°C. 







3.8. Blocking and antibody treatment 
After transfer the membrane was placed in an incubation box with 
6 mL of Odyssey blocking buffer (CAT#927-40000 Odyssey®). The 
membrane was gently shaken for one hour. Primary antibodies were 
prepared by diluting the primary antibody of interest and mouse 
monoclonal GAPDH (CAT# ab9484 Abcam®) at 1:6000 antibody in 
Odyssey blocking buffer with 0.2% Tween 20.  Then, the blocking buffer 
was poured off and the primary antibody was added. The membrane was 
incubated with the primary antibody and gently shaken overnight at 4°C. 
The following rabbit polyclonal antibodies and dilutions were used: BMP3 
(CAT#ab71500 Abcam®) at 1:1000, BMP7 (CAT#ab93636 Abcam®) at 
1:200, SMAD1 (CAT#ab63356 Abcam®) 1:500, phosphorylated SMAD1 
(CAT#ab97689 Abcam®) 1:500, SMAD3 (CAT#ab40854 Abcam®) 1:1000, 
phosphorylated SMAD3 (CAT#ab51451 Abcam®) 1:1000, SMAD4 
(CAT#9515 Cell Signaling Technology®), INHBA (CAT#ab56057 
Abcam®), and phosphorylated ERK1 and ERK2 (CAT#ab47339 Abcam®) 
1:1000. These antibodies had been previously been validated on human 
tissue according to suppliers data. 
After incubation, the primary antibody solution was poured off 
and membrane was washed with 1X Tris buffered saline (TBS) with 0.1% 
Tween 20 and gently shaken for 5 minutes at room temperature. This was 
repeated an additional three times. Secondary antibodies used were goat 
anti-mouse IgG2b IR Dye 680 LT (CAT# 9268052 Licor®) and goat anti-
rabbit IgG IRDye 800CW (CAT#92632211 Licor®) and diluted in 6 mL of 
Odyssey Blocking buffer at the following concentrations; 1:25000 and 
1:10000 respectively. Secondary antibody solution was added to the 
membrane in the incubation container and left at room temperature 
protected from light for one hour with gentle shaking. 
After secondary antibody incubation, the antibody solution was 
removed and the membrane was washed with 1X Phosphate buffer 
solution (PBS) with 0.1% Tween 20 and shaken for five minutes at room 
temperature whilst protected from the light. This was repeated an 
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additional three times. The membrane was finally rinsed briefly in 1X PBS 
solution, and then dried between two pieces of Whatman paper before 
scanning. The membrane may be stored at 4°C protected from the light to 
allow for scanning at a later date and rescanning if required. 
 
3.9. Imaging and analysis 
Membranes were imaged on an Odyssey image scanner with 
Licor® Image Studio at 700nm, and 800nm wavelengths at the following 
intensities 2.0 and 2.5 respectively. Images were converted from colour 
(Figure 3.1) to grey scale to better visualize signalling and bands (Figure 
3.2). A single channel was selected to allow for visualization of a single 
antibody (Figure 3.3). A representative band was selected for each protein 
(Figure 3.4) and a box was drawn that would fit this and the majority of the 
other bands (Figure 3.5).  If there was an irregular band that could not be 
covered by the drawn box, then the size of the box was changed to best 
ensure that the signal profile was encapsulated (Figure 3.6 and 3.7). This 
was repeated by selecting for the other wavelength and repeating. 
Background removal was attempted multiple times with the following 
settings, median top-bottom, average top-bottom (Figure 3.8) at 1 mm and 
3 mm (Figure 3.9), and user-defined (Figure 3.10). Signalling levels were 
then normalised to GAPDH and mean, standard deviation and coefficient 
of variation was calculated. The background removal method that 
consistently produced the lowest coefficient of variation was selected as the 
background removal method. Normalising was done by expressing the 
protein of interest over GAPDH levels in the same channel and GAPDH 
was further normalised for analysis by expressing individual GAPDH 
levels over the highest GAPDH signal for category. Non-phosphorylated 
SMAD signalling levels were also calculated when possible by expressing 
phosphorylated SMAD over total SMAD. Statistical analysis of signalling 
levels was done with Graphpad Prism consisting of X Y analysis providing 
the means of normalised signalling levels and the Statistical significance 
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was determined by Student’s t-test where p<0.05 was statistically 
significant and plotted as a bar graph with SEM. If bands were saturated or 
the signal was too intense, the membrane was rescanned with intensities of 






Figure 3.1: Unaltered Western blot of pSMAD1 (CAT#ab97689 
Abcam®) at 1:1000 (800 nm channel marked “1”) and GAPDH (CAT# ab9484 
Abcam®) at 1:6000 (700 nm channel marked “2”) image on Licor® Image Studio 
Lite with two colour detection.  
 
 
Figure 3.2: Western blot image converted to grey scale to better see 
bands. Grey scale selection circled and marked “1”  at 800 nm channel and “2” at 







Figure 3.3: One channel is selected to allow measurements of intensity 
to be specific to that wavelength and therefore the protein of interest. (800 nm 
channel  marked“1”) (deselected channel  marked “2”) 
 
 
Figure 3.4: “Draw Rectangle” (circled and marked “1”) is selected and 
placed over most representative band for that wavelength to provide a sample 
area. Size of the sampling area is adjusted to encompass the entire signal 








Figure 3.5: Rectangle is copied and placed over all bands in that 
wavelength. Signal intensity is checked under “Profile” to see if it is entirely in 
sampling area. If a band does not fit in rectangle, then rectangle is resized based 
on “Profile” in X and Y directions. 
 
 
Figure 3.6: Sampling area drawn as in Figure 3.4 with other channel 
(700 nm) selected (circled and marked “1”) and previous channel 





Figure 3.7: This sampling area is duplicated for all other lanes. Again 
sampling area is checked against “Profile” to ensure entirety of signal within 
the rectangle. 
 
Figure 3.8: Background removal method selected (dropdown menu 






Figure 3.9: For “Median” and “Average” background removal method 
“Top/Bottom” (circled marked “1”) removal is selected with border widths  
being set at 3 mm or 1 mm for “Median”, and 1 mm for “Average” (border width 
in dropdown menu circled and marked “2”). 
 
Figure 3.10: For “User-Defined” background removal another 
rectangle, with both channels selected for, is drawn over a blank or 
representative area and assigned as a blank by “Assign shape” (circled with user 





In this study, gene expression in low-grade tumour tissues was 
compared to that of high-grade tumour tissues to screen for potential 
candidates that may be involved in the progression of prostate cancer. 
 
	  
4.1. Total RNA extraction and cDNA 
conversion 
Total RNA was extracted from 4 low-grade tumour biopsy tissues 
and 8 high-grade tumour biopsy tissues. A 260/280 ratio of greater than 2 
is considered pure and free from other contaminants such as proteins 
which absorb at 280 nm whereas a 260/230 ratio of above 2 is considered 
pure and free of contaminants that absorb at 230 nm such as phenol and 
guanidine salt. The cDNA concentration, 260/230 ratio and 260/280 ratio, 
as well as patient details such as Gleason score and Gleason pattern can be 








4.2. TGF-β focussed RT-qPCR 
No statistically significant differences between the low-grade 
prostate cancer and the high-grade prostate cancer tissue were observed for 
any genes in the array. However, expression of some genes, showed >2 
between low and high-grade cancer which could be considered as 
biologically significant (Figure 4.1). TGF-β genes that were up-regulated 
were activin A (INHBA) and BMP3. TGF-β superfamily genes that were 
down-regulated were BMP7 and BMPER. SMAD3 was down-regulated 
and was the only intracellular signalling molecule altered by a fold change 
of >2 between low and high prostate cancer tissue. Proteins that affect cell 
function that were biologically altered were, GSC and PLAU being up-
regulated and JUN and HIPK2 being down-regulated in high grade 
compared to low grade. Other up-regulated genes included CDKN2, a 
tumour inhibitor gene and COL1A2, a gene that encodes collagen type-I. 
Full Gene list in Appendix 3. Full results of fold regulation of high grade 
prostate cancer tissue to low grade prostate cancer tissue, as well as 
comparing high grade normal adjacent tissue to low grade normal adjacent 




Figure 4.1: Genes that were altered by >2 fold changes in TGF-β 
focussed RT-qPCR when high grade prostate cancer tissues were compared with 
low grade prostate cancer with low grade. No statistically significant differences 
(p<0.05) were found. Data are shown as mean fold difference with SEM, N= 4 
and 8 for low grade and high-grade prostate tumour tissue respectively. Gene 

































































































4.3. Protein extraction 
Protein was extracted from 6 samples, 3 low and 3 high-grade 
prostate cancer tissues. Data for protein concentration and composition of 
aliquots for Western blots, including mass of sample, amount of RIPA 
buffer amount used for homogenisation, protein concentration, protein 
amount in Western blot, water amount, and DTT amount are shown in 
Appendix 6. 
 
4.4. Western blots  
Western blots were performed to validate the array data. 
Candidate proteins examined were INHBA, BMP3 and BMP7. These 
ligands were chosen due to being 2 fold up or down-regulated TGF-β 
superfamily members observed in the TGF-β RT-qPCR. Western blots were 
also performed to validate the signalling pathways used concentrating on 
the canonical signalling molecules of SMAD3, SMAD1, their 
phosphorylated forms and SMAD4 and the non-canonical pathway pERK1 
+ pERK2. Western blots were performed for each protein normalised to 
GAPDH to control for any differences in protein loading. Full Western blot 
results may be found in Appendix 7.  GAPDH bands were expected to be 
≈40 kDa in size and were found to be consistently expressed at 38 kDa. 










The Western blot for BMP3 (Figure 4.2) showed no significant 
alteration in protein expression between low-grade tissue and high-grade 
tissue. Observed BMP3 bands showed two bands in close proximity 
between 52 kDa and 38 kDa this differed from the expected BMP3 band 
sizes at 55 kDa with a second cleaved fragment at 16 kDa.  
 
Figure 4.2: Western blot showing changes in BMP3 between high and 
low grade prostate cancer. A) BMP3 protein expression normalised to GAPDH. 
Bars represent mean and error bars indicate SEM n=3. Ns denotes p>0.05 
between low grade and high grade. B) Western blot of BMP 3 with low grade 
samples on left and high grade samples on right. Each set of samples includes a 
ladder in channels 1, a blank control in lanes 5, and 3 samples in lanes 2, 3, and 












































SMAD3 Western blot (Figure 4.3) showed no statistically 
significant alteration in signalling between low-grade samples and high-
grade samples. This was contrary to TGF-β focussed RT-qPCR, which 
showed a reduction of SMAD3 gene expression in high-grade samples 
compared to low-grade samples. The SMAD3 band was observed at 52 




Figure 4.3: Western blot showing changes in SMAD3 between high 
and low grade prostate cancer. A) SMAD3 protein expression normalised to 
GAPDH in low and high-grade prostate cancer tissue. Bars represent mean with 
error bars indicating SEM n=3. Ns denotes p>0.05 between low grade and high 
grade. B) SMAD3 Western blot results with low-grade samples on left and high 
grade on right. Each set of samples includes a ladder in lane 1, a blank control in 
lanes 5, and 3 samples in lanes 2, 3, and 4. 






































The Western blot for phosphorylated SMAD3 Western blot 
(Figure 4.4) showed a statistically significant reduction in pSMAD3 
protein expression in the high grade tumour samples compared to 
the low grade tumour samples (p<0.05). Like SMAD3, the pSMAD3 
band was observed at 52 kDa, which corresponded to the expected 
size of 48 kDa. 
   
Figure 4.4: Western blot showing changes in pSMAD3 between high 
and low grade prostate cancer. A) Phosphorylated SMAD3 protein expression 
normalised to GAPDH in low and high grade prostate cancer tissue between 
low grade tissue compared to high grade tissue. Bars represent mean with error 
bars indicating SEM n= 3. * Indicates statistically significant results where 
p<0.05 B) pSMAD3 Western blot results with low grade samples left and high 
grade right. Low-grade sample grouping consists of a ladder in channel 1, a 
blank control in lane 2 and samples in lane 3, 4, and 5. High-grade sample group 
includes a ladder in lane 1, a blank control in channels 5, and 3 samples in lanes 
2, 3, and 4.  
 






































SMAD3 activation was determined by the ration of pSMAD3 expression 
over SMAD3 expression. There was a significant reduction in SMAD3 
activation (p<0.05)(Figure 4.5)  
 
 
Figure 4.5: Total SMAD3 signalling expressed as pSMAD3/SMAD3. * 
Indicates p<0.05 comparing total SMAD3 signalling between low grade tissue 
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*
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The Western blot for SMAD4 (Figure 4.6) showed a statistically 
significant reduction in SMAD4 protein expression in high-grade samples 
compared to low-grade samples (p<0.005). SMAD4 band was observed 




Figure 4.6: Western blot showing changes in SMAD4 between high 
and low grade prostate cancer. A) SMAD4 protein expression to GAPDH in low 
and high-grade prostate cancer tissue.  Bars indicate mean with error bars 
indicating SEM n=3. ** Indicates p<0.005 between low grade tissue compared to 
high grade. B) SMAD4 Western blot with a ladder in lane 1, a blank control in 
lane 5, and 3 samples in lanes 2, 3, and 4. 
 




































Phosphorylated SMAD1 Western blot (Figure 4.7) showed 
no statistically significant alteration in protein expression level. As 
expected pSMAD1 was band size was observed at 52 kDa. 
  
 
Figure 4.7: Western blot showing changes in pSMAD1 in high and low 
grade prostate cancer A) Phosphorylated SMAD1 protein expression normalised 
to GAPDH. Bars indicate mean with error bars indicating SEM n=3. Ns denotes 
p>0.05 between low grade and high grade B) Each set of samples include a 













































The Western blot for phosphorylated ERK1 and ERK2 Western 
blot (Figure 4.8) showed no significant alteration in protein expression level 
between low grade and high grade tumour sample. The expected sizes of 
pERK1 and pERK2 are 44 kDa and 42 kDa and doublet bands were 
observed at around 42 kDa. 
   
 
Figure 4.8: Western blot showing changes in pERK1/2 between high 
and low grade prostate cancer A) Phosphorylated ERK1 and ERK2 protein 
expression normalised to GAPDH. Bars indicate mean with error bars indicating 
SEM n=3. Non-significance is denoted with ns where p>0.05 between low grade 
and high grade. B) Western blot of pERK1 and pERK2. Low grade samples on 
left and high grade samples on right. Each set of samples includes a ladder in 
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Results were unable to be obtained for BMP7, activin A (INHBA) 
and SMAD1. SMAD1 and BMP3 Western blots had significant non-specific 
staining and bands, INHBA showed no bands.  
BMP7 Western blot (Figure 4.9) had non-specific band from 76 
kDa to 17 kDa, therefore was unable to draw any result. GAPDH band 
appears at approximately 38 kDa. 
 
Figure 4.9: Western blot of BMP7 in high and low grade prostate 
cancer. BMP7 Western blot (1:200), coloured green. Many non-specific bands 
from 76 kDa to 17 kDa with BMP7 antibody. GAPDH band appearing at 
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SMAD1 Western blot (Figure 4.10) showed no staining, previous trials with 
this antibody at suggested dilutions of 1:1000 and 1:500 had similar results 
with no bands appearing at 1:500 dilution and faint bands at 1:1000 
dilution. 
 
Figure 4.10: SMAD1 Western blot (1:1000), expected to be coloured 
green, no staining was observed 800 nm wavelength. GAPDH band appearing at 
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INHBA Western blot (Figure 4.11) showed no bands with INHBA 
antibody and GAPDH bands appearing at 38 kDa, due to not having a 
positive control, this study is unable to determine the reason behind this 
result. 
 
Figure 4.11: INHBA Western blot (1:1000) expected to be green, no 
staining was observed at of 800 nm wavelength. GAPDH band appearing at 
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This discussion will go through the techniques used in this study, 
their limitations, and then the results obtained. These techniques include 
the usage of human tissue, the TGF-β focussed RT-qPCR array and 
Western blots. Next in this chapter the findings will be brought together 
and I will discuss what meaning may be drawn from these results. Future 
directions will also be discussed providing possible methods to expand on 

















5.1. Human Tissue 
The use of human prostate biopsy samples in this study was an 
important aspect as they better represent the disease in vivo compared to 
cell culture. In vivo the prostate is comprised of multiple cell types, affected 
by other exogenous factors from other tissues and organs in the system as a 
whole and is an important consideration in the behaviour of prostate 
cancer, as the cells exhibit different structures, functions and behaviours 
(101, 102). The heterogeneous nature of human tumours is also an 
important consideration, the variability between individual tumours is an 
important concept and highlights a need to do large scale human tissue 
studies to gain a better understanding of total variations as well as the 
distribution in TGF-β superfamily related signalling (105, 106). The use of 
the same samples mRNA and protein throughout the entire experiment is a 
strength that to a degree controls for this possible variability to a degree, 
reducing alteration not covered by the initial gene array that may be 
introduced by other tissue sources. 
 
5.1.1. Limitations of Human tissue 
However the usage of human tissue despite its strengths 
mentioned prior also has limitations. Despite the fact that it more closely 
resembles the in vivo state, the same variations that the tissues exhibit is 
also a limitation, especially considering the fact that this study uses such a 
small sample size. The samples used may not be representative of the 
actual population. To address this issue future studies would require larger 
sample sizes. This also holds true to the physical size of the samples. Due 
to the same samples being used for multiple techniques it was difficult to 
control for possible mistakes or variations in individual trials. This 
restriction in protein and sample quantity available for Western blot 
analysis limiting the ability to retest as shown by the Western blots for 
INHBA, BMP3 and SMAD1. The samples, also in conjunction with not 
being fully representative of the population, may only truly be 
69 
representative of the tumour state, as the tissue obtained is a snapshot in 
time of that tumour, this invariably affects the results of the techniques 
used on this tissue. This could alter actual results, as the functions that the 
tissue may be exhibiting may not be totally representative of the total 
processes that are going on. Further issues that may confound the results 
could be the degradation that the tissue may exhibit. The tissue was 
preserved in Tissue Tek® O.C.T compound and frozen, though this may 
reduce the tissue degradation, the actual tissue integrity would also be 
disrupted, preventing or limiting the ability to do techniques such as 
immunohistochemistry. The presence of this compound may affect results 
if not fully removed from samples. The lack of controls is another 
limitation that exists for the usage of human tissue especially in the realms 
of prostate cancer research. There is a lack of controls representing a truly 
normal state due to the difficulty obtaining healthy prostate tissue as 
opposed to the normal adjacent tissue. Normal adjacent tissue, due to its 
proximity to the tumour is exposed to the factors that the tumour tissue 
may express, hence may be affected (105). Evidence shows more variations 
in genomic expression of normal adjacent tissue of the low-grade tissue 
compared to high-grade tissue as compared to the supposed abnormal 
tumour tissue of the same comparison Appendix 4. Another issue, is that 
this study had no way to identify if the TGF-β superfamily related 
signalling changes observed are specific to prostate cancer and not related 









5.2. TGF-β focused RT-qPCR array 
The TGF-β focussed RT-qPCR array allowed the bulk examination 
of TGF-β superfamily related gene expression. A strength of this initial 
technique is the large data output from a limited amount of tissue sample 
and simplicity. This is especially important considering how structurally 
and functionally similar these genes and their protein products are as well 
as the interrelations they may have. Due to this, this initial approach has 
further transferability in future possible studies being applied to other 
diseases, and protein families. The comparisons were between low-grade 
prostate cancer to high-grade prostate cancer. Comparisons to normal 
adjacent tissue as a control were not performed, due to the possibility that 
normal adjacent tissue may have more aberrant signalling and did not 
represent a “normal” control (105). Large variations in normal adjacent 
tissue maybe a reaction due to their close proximity to tumour tissue and 
the factors that the tumour may release. Therefore such comparisons 
between normal adjacent tissue and tumour tissue were omitted from this 
study. The comparison between low grade and high grade prostate cancer 
may also benefit in better teasing out possible mechanisms or markers that 
would enable the ability to diagnose whether a tumour is progressing to a 
more aggressive phenotype. 
 
5.2.1. Limitations with TGF-β focused RT-qPCR array 
A limitation of the usage of the commercially available array is 
that it did not encompass all genes that may be associated with the TGF-β 
superfamily related signalling. Genes not in the original array include 
SMAD inhibitors, SMAD6 and SMURF2, and TGF-β receptors such as TGF-
βRIIB and TGF-βRIIC. Other members of the non-canonical signalling 
molecules that were not only absent from the initial array, but also heavily 
implicated with the progression of prostate cancer, include NFκB (64), ERK 
(11), beta-catenin, p38 (8), and p58 (86). This was partly addressed with the 
inclusion of pERK1 and pERK2 for testing in the proceeding Western blots. 
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Another issue that was partially addressed with the inclusion of the 
Western blot is that genomic alterations in expression do not necessarily 
mean alterations in functionality or signalling, An example of this is the 
TGF-β receptors and canonical pathways. These components of TGF-β 
signalling depend on phosphorylation to activate them, for the receptors a 
type II receptor is phosphorylated by ligand binding which then recruits 
the type I receptor, again by phosphorylation. The same principle is central 
to SMAD signalling, for example, SMAD2/3 is recruited by the activated 
receptor, which then recruits SMAD4 which translocates to the nucleus to 
alter gene transcription. 
Another limitation with the usage of the RT-qPCR array, in this 
particular study, is again that it is not causative and is correlative. This 
technique is unable to determine if the changes observed are the cause of 
observed cancerous phenotype or merely a by-product or response to the 
cancerous phenotype. The array is also dependent on the primers it 
utilizes, therefore any mutations to genes may either result in the genes not 
being represented as the primers were unable to amplify the gene, or 
unable to show any mutations that the gene might have. 
 
5.2.2. Results of TGF-β RT-qPCR 
The array provided no statistically significant result, so instead the 
genes whose alteration in expression exceeded two-fold from the 
housekeeping gene expression, were deemed most biologically relevant. 
Biological relevance was deemed 2-fold up or down-regulation of genes in 
the high grade tumour tissue compared to the low grade tumour tissue, 
this was chosen as the ligands observed have potent effects on the tissue 
that they are exposed to (112). Observed changes were an up-regulation of 
INHBA, GSC, PLAU and BMP 3 and a down-regulation of HIPK2, BMP7, 
BMPER, SMAD3, EMP1, and TGFBRAP1. These observed fold-change 
differences in gene expression also correlate with their known functions 
and the phenotype of the disease progressing from low-grade prostate 
cancer to high grade.  
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Of the genes with an altered expression of greater than 2 fold, GSC 
and PLAU, up-regulation is consistent with a more aggressive phenotype 
as described in the literature. GSC, a target of canonical activin signalling, 
is involved with Spemann organiser, an essential gene during gastrulation 
but whose activation in mature tissue may help to induce EMT and 
increase cell motility (50). PLAU, another gene involved in EMT, is 
responsible for the breakdown of the extracellular matrix, thus increasing 
the invasive capability of the tumour. PLAU is a target of both canonical 
(Figure 5.1) and non-canonical TGF-β superfamily signalling (Figure 5.2) 
(64). EMP1, another anti-proliferative gene was also found to be down-
regulated, EMP1 is responsible for the formation of tight junctions as well 
as regulating capase-9 and VEGF expression, thus allowing apoptosis and 
the inhibition of angiogenesis, respectively. This association is consistent 
with the literature, where EMP1 expression prevented the PC3 prostate 
cancer cell line from invasion and proliferation (113). Another proapoptotic 
gene, HIPK2 was down-regulated. HIPK2 regulates TGF-β induced cJUN-
N-terminal kinase activation (JNK) activation and apoptosis (Figure 5.3) 
(69). This decrease in apoptotic ability along with a greater capacity of 
invasion is beneficial for tumour progression. 
Additional ligand genes of interest included INHBA, BMP3, 
BMP7, and BMPER. INHBA and BMP3 were both up-regulated. INHBA 
the gene that encodes for activin A, a pleiotropic protein which is 
implicated to be protective against low grade prostate cancer and 
promotive of the disease in high grade forms of the disease (3, 53). BMP3, a 
BMP inhibitor gene that is shown to antagonise activin A signalling, 
highlights a possible interaction between the two. BMP3 has been shown to 
have a role in promoting EMT (83, 89). 
Down-regulated ligand genes were BMPER and BMP7 (Figure 
5.4).  BMPER is another BMP inhibitor, like BMP3 it is associated with 
controlling a tumour’s ability to invade and proliferate. This ability was 
demonstrated to promote carcinoma invasion abilities (114) but is down-
regulated at a genomic level in this study. BMP7 which has been shown to 
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be an inhibitor of prostate cancer and TGF-β associated EMT is found to be 
down-regulated in prostate cancer. It acts by counteracting SMAD3/4 
activation and can inhibit metastasis to the bone (52, 92, 93).   
Altered intracellular signalling molecules included JUN, SMAD3, 
and TGFBRAP1. JUN, a non-canonical signalling molecule which in 
conjunction with c-FOS, form AP1 signalling. JUN signalling may be linked 
with both the inhibition of EMT and the inhibition of SMAD2/3, and 
whose expression is induced through SMAD3 canonical signalling (Figure 
5.5), potentially forming a negative feedback loop. Also reduced was 
SMAD3 the canonical member of the TGF-β and INHBA signalling 
pathway. The hypothesis that SMAD3 signalling is affected is further 
strengthened by the reduction of TGBRAP1, a chaperone protein for 
SMAD4. The mutation of TGFBRAP1 has been shown to interfere with 
TGF-β and activin signalling (115). Therefore the inference that can be 
made based on the RT-qPCR array data is that there is potentially some 
alteration in canonical SMAD3 signalling resulting in a possibility that the 
progression of prostate cancer may be associated with decreased  canonical 







Figure 5.1: Simplified TGF-β canonical signalling pathway, showing 
genomic expression levels from TGF-focussed gene arrays. TGF-β binds to type-
II receptor, which recruits type-I receptor via phosphorylation. TGF-β has a 
shared potential to activate SMAD1/5/8 pathway shared with BMP. Despite this 
potential to signal via SMAD1/5/8, the preferred pathway is via SMAD2/3. 
Shown are potential targets, these targets ave diverse effects, such as controlling 
tissue maintenaince via induction of apoptosis, or functions that benefit 
metastasis such as PLAU. Genomic expression levels are average fold changes of 


























































Figure 5.2: Simplified TGF-β non canonical pathway showing genomic 
expression levels in brackets based on TGF-β focussed RT-qPCR array. 
Activation of the non-canonical pathway inhibits SMAD signalling. Same 
receptors are activated however SMAD signalling is inhibited by SMAD7 
allowing the further activation of the various components of the non-canonical 
pathway. Also highlighted in the diagram is the multitude of possible effects of 
the non-canonical signalling pathway. Genomic expression levels are average 
























































Figure 5.3: Simplified common apoptotic pathway shared by TGF-β 
and BMP, genomic expression of TGF-β focussed RT-qPCR array is shown in 
brackets. Apoptotic pathway is activated by non-canonical pathway sharing 
MKK3/4/7, as described by Hofmann et al. (2003) (69). Genomic expression 
levels are average fold changes of the high grade tumour compared to low grade 
















































Figure 5.4: Diagram of simplified BMP pathway showing both a 
canonical SMAD pathway and an example of non-canonical component. 
Genomic expression levels from TGF-β focussed RT-qPCR array in brackets. 
Canonical SMAD1/5/8 pathway may inhibit TGF-β/activin related SMAD2/3 
pathways. Genomic expression levels are average fold changes of the high grade 



































Figure 5.5: Diagram of simplified canonical activin signalling, genomic 
expression of TGF-β focussed gene array is shown in brackets. Activin A binds 
to type-II receptor ACVR2A, which recruits type-I receptor ACVR1. Activated 
receptor dimer then phosphorylates SMAD proteins which translocate to the 
nucleus to activate gene transcription. Possible results of canonical activin A 
signalling include controlling cell cycle, controlling SMAD2/3 signalling by up-
regulating AP1, or inducing cell migration through GSC. Genomic expression 
levels are average fold changes of the high grade tumour compared to low grade 












































Figure 5.6: Diagram of simplified compiled non-canonical activin 
signalling, genomic expression levels from TGF-β focussed RT-qPCR arrays 
shown in brackets. The diagram highlights the multiple non-canonical 
pathways that may be activated as well as interactions with each other and their 
relevance to cancer biology. Diagram based on Loomans and Andl (2015) (8). 
Genomic expression levels are average fold changes of the high grade tumour 




























































5.3. Western blotting 
An important aspect of this study is that the changes in gene 
expression were supported by examining changes in protein levels. By 
examining protein expression one is able to validate actual protein amount 
and signalling. This concept is especially important when considering 
some proteins have an active form, and the possible disparity between 
genomic and actual protein concentration. The chosen proteins for Western 
blot analysis were; INHBA, BMP3, BMP7, SMAD3, pSMAD3, SMAD1, 
pSMAD1, SMAD4, and pERK1 and pERK2. INHBA, BMP3 and BMP7 were 
chosen for validation as they were the members of the TGF-β superfamily 
that demonstrated a 2-fold change in gene expression. The intracellular 
signalling molecules of SMAD3, SMAD1, their phosphorylated forms, and 
SMAD4 which form the components of canonical pathway were chosen to 
both validate the observed reduction in SMAD3 gene expression, and 
observe possible changes in actual activation and expression levels.  
These intracellular signalling molecules chosen are associated 
pathways that TGF-β superfamily may take. SMAD3 is the preferred 
canonical pathway of TGF-β and activin A, SMAD1 is the preferred 
canonical signalling molecule of the BMPs. These molecules are activated 
by phosphorylation when their respective ligands activate their receptor 
complexes. The phosphorylated intracellular signalling molecules will then 
go on to recruit SMAD4 causing it to translocate to the nucleus beginning 
gene transcription. By observing the protein expression of these canonical 
pathway components, we can see if alterations in activation or expression 
may contribute or at least correlate with the progression of prostate cancer 
(55, 116, 117). Phosphorylated ERK1 and ERK2 were also chosen for 
Western blot analysis as they are an example of non-canonical signalling 
molecules that are associated with the TGF-β superfamily and also heavily 
implicated in prostate cancer (11, 91, 118). 
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5.3.1. Limitations with Western blotting 
There were many limitations with this study’s usage of Western 
blots. The sample sizes used with the Western blots were a further 
reduction in size from the number from the initial samples used in the 
previous arrays, this could be interpreted as a potential loss of data which 
may affect the significance of the final results. The use of Western blots is 
also dependent on the amount of protein that a sample has, which is 
subject to degradation over time. The same may be said for the dependency 
on antibodies. Specificity of the antibody is another factor that Western 
blots depend on, poor specificity may result in nonspecific binding. Blot 
quality is another factor that greatly affects the accuracy of the results 
obtained as sampling area may be distorted, This is apparent in Western 
blot results that exhibited smears and field effects. Another aspect of this 
dependency on antibody is shown in the BMP3 results. The unexpected 
bands observed at 38 kDa are not reported using that antibody (119). Due 
to the inability to find other studies using the BMP3 antibody used in this 
study, validation of this antibody with human BMP3 as well as testing 
another BMP3 antibody that may be more specific for human BMP3 should 
be undertaken to confirm these data. 
Results were not able to be obtained for BMP7, SMAD1 and 
INHBA. Western blots for BMP7 and SMAD1 exhibited a lot of nonspecific 
bands and smears despite using the antibody according to the 
manufacturer recommendations and trialling BMP7 at 1:1000 and SMAD1 
at 1:1000 and 1:500 concentrations in hopes of optimising the process. 
INHBA antibody did not bind, so no bands were observed. This antibody 
had been previously used by the lab group so no initial trial was 
attempted. Despite using previously these optimised dilutions stated, no 
positive control was used and therefore this study was unable to find a 
reason behind for the lack of signal. BMP7 nonspecific binding may be due 
to multiple forms of the BMP7, or that the protein sample had been 
degraded. Another possible reason for the non specific bands may be that 
the primary antibody concentration was too high. Possible reasons for the 
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lack of binding for SMAD1 and INHBA the primary antibody did not 
recognise the proteins of interest, the protein of interest was not abundant 
in tissue or there was a poor transfer of protein to membrane. This loss of 
data greatly hindered this study, though with the data obtained inferences 
may be made regarding disease mechanism and progression. Western blots 
also require sufficient amounts of protein within a sample, in samples of 
small size or with low protein concentration this limits the effectiveness of 
each trial as well as limiting the amount of trials that can be undertaken as 
was evident in this study. The use of Western blots in this study is also 
only correlative much like the previous arrays. It is unable to, in this case, 
determine the reason for the decrease in SMAD3 activation or SMAD4 
protein expression. Another limitation regarding the non-causal usage of 
Western blotting in this study is even if the antibody may bind to the 
protein of interest there may be alterations to protein structure that may 
occur that affect functionality but not the antibody binding. Conversely if 
the protein is so malformed that the antibody is unable to bind to it, this 
reason would be not shown in the Western blot. 
 
5.3.2. Western Blot Results 
No changes in protein levels of BMP3, pSMAD1, and pERK1 and 
pERK2 were observed. This could either mean; that these proteins have no 
effect on the progression of cancer, or that these pathways unhindered 
contribute to the progression of prostate cancer. The unexpected bands 
observed in BMP3 Western blot warrants further testing with another 
antibody or by testing the antibody with a positive human BMP3 control to 
determine if BMP3 was actually detected. Total SMAD3 exhibited no 
significant difference between low grade and high grade contradictory to 
the initial gene array, highlighting the importance of validating genomic 
data with techniques such as Western blotting. 
Even though there was no significant alteration in total SMAD3 
protein expression there was however a reduction in pSMAD3 activation. 
This could be interpreted as a reduction in pSMAD3 signalling, though 
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further study on the targets related to SMAD3 or the expression of 
molecules that interact with it would need to be done. 
Another interesting finding in this study was the statistically 
significant reduction in SMAD4 expression in high grade samples 
compared to low grade in the Western blots. Alterations in SMAD4 have 
been associated with the progression of prostate cancer. A possible reason 
implicated in the literature include mutations in SMAD4 (58, 60). Such a 
reason would implicate decreases in all canonical signalling due to shared 
SMAD activation of SMAD4. 
 
5.4. Integration 
Though this study is unable to find any causative link between 
prostate cancer progression and reductions in SMAD3 signalling, the 
following inferences may be made. SMAD3 is an intracellular molecule that 
is part of the canonical signalling pathway for TGF-β and activin A. 
SMAD3 activation is dependent on being phosphorylated. A reduction in 
pSMAD3 expression does not correlate with an increase in either pSMAD1 
expression, or pERK1 and pERK2 expression. As mentioned prior, this 
could mean that these pathways have no effect on prostate cancer 
development or that the reduction in SMAD3 activation has merely 
reduced the ability to inhibit pSMAD1 or ERK signalling in prostate cancer 
progression. Another strong possibility is that other non-canonical 
pathways that were not tested may cause this reduction in SMAD3 
activation or are up-regulated by the reduced SMAD3 signalling.  
Though this study was unable to find a reason for the decrease in 
SMAD3 activation or its direct effect on cancer progression, it has at least 
formed a possible direction for future studies to take. In addressing 
potential clinical uses of SMAD3 and pSMAD3 as a biomarker, because it is 
an intracellular signalling molecule and the fact that reductions in 
pSMAD3 expression are not prostate cancer specific it cannot be used as a 
circulating biomarker. Instead, if reductions in SMAD3 signalling were to 
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be used as a biomarker in diagnosing the progression of prostate cancer, it 
would need to be used in conjunction with other methodologies such as 
examining reductions in SMAD3 activation in prostate tumour biopsies. 
This would consist of examining reductions in total SMAD3 signalling over 
multiple tumour biopsy samples, making it susceptible to the same 
limitations that affect prostate biopsies. 
Another point of interest is the decrease in SMAD4 protein 
expression, though the quality of the Western blot may affect the overall 
credibility of the result obtained. Despite the overall blot quality, the result 
obtained for SMAD4 do warrant further investigation. A part in this is that 
alterations and mutations in SMAD4 function are associated with the 
progression of cancer and supported in the literature (3, 58, 59, 60). This 
reduction in SMAD4 may also denote a total reduction in canonical 
signalling regardless if it is due to SMAD1 or SMAD3 activation. SMAD4 
and therefore is another potential target for future studies and hinting a 















5.5. Future Studies 
Future possible directions may involve improving on the previous 
limitations mentioned above. The first issue that would need to be 
addressed would be the sample size. By increasing sample size, the study 
would be better equipped to handle possible variations that might occur 
between individuals as well as provide a possible distribution of the 
variations that may occur in TGF-β superfamily related signalling. A larger 
sample size may also better direct potential targets for additional study 
with statistically significant targets.  Another issue that may address the 
possible variations in human samples includes the usage of a positive 
control. Another issue that can be addressed is comparing the gene and 
protein expression in other prostate pathologies with prostate cancer. This 
would show that any variations observed are specific to prostate cancer 
alone, a limitation with the current biomarker of prostate specific antigen 
which is prostate specific but not prostate cancer specific which may 
increase due to age, benign prostatic hyperplasia, or with lifestyle choices, 
as well as better associating an observed alterations in gene or protein 
signalling with prostate cancer and its development.  
A possible expansion or alteration for future studies could include 
examining different genes or proteins. It was shown that both the initial 
array used was not as encompassing of TGF-β superfamily family related 
signalling, combined with the discrepancies between genomic and protein 
data thus allows for further expansion of proteins or signalling pathways 
to test. As mentioned prior there is a possibility that there may be an 
increase or an alteration in non-canonical signalling, hence future studies 
could concentrate on possible non-canonical pathways up-regulated in 
prostate cancer. Additional molecules that can be tested include SMAD 
inhibitors such as SMAD6 and SMAD7, as well as SMURF1 and SMURF2 
looking for active forms of the molecules denoting in inhibition of SMAD 
pathways. As well as SMAD inhibitors, it is also worthwhile to examine the 
protein expression of receptors as there were receptor isoforms that were 
not covered by the initial array. The receptors and the complexes they form 
86 
add an additional layer of complexity to TGF-β signalling due to the 
activation which requires an activated type-II receptor to bind and then 
activate a type-I receptor. Additional expansions for future studies is to 
look at target genes or proteins that are associated with normal TGF-β 
superfamily function that relate to either tissue maintenance, such as 
apoptotic genes like DAP- kinases or, and genes associated with the 
progression of cancer, such as PLAU. By examining the intracellular 
pathways used and the target proteins activated one would be better able 
to determine a mechanism for disease progression, and from that be able to 
better determine the prognosis of the disease as well as possible treatments. 
Additional future studies could be to add immunohistochemistry 
to determine localization of proteins potentially hinting at possible spatial, 
and causative relations with alterations in protein concentration and 
signalling. Immunohistochemistry would be especially useful in testing 
proteins that translocate in order to enact an effect, like SMAD4 which 
translocate to the nucleus. A similar approach would be confocal-
immunohistochemistry to look for the co-expression of proteins to examine 
the possible relationship or interactions between proteins. Such an 
approach would be useful for examining the relationship between ligand 











In conclusion, this study showed that high grade prostate cancer 
tissue had a decrease in SMAD3 activation and SMAD4 protein levels 
when compared to low grade prostate cancer tissue. The decrease in 
SMAD3 activation and SMAD4 protein levels could result in increased cell 
growth, thus aiding cancer progression. However this study was unable to 
determine if altered TGF-β superfamily expression was responsible for this 
reduction in SMAD3 activation or SMAD4 expression. Also observed was 
that the alterations of protein expression did not correspond with 
alterations in mRNA expression, showing discrepancies between protein 
and genomic data. This study has shown possible directions for future 
studies, either concentrating on examining factors that affect SMAD3 
activation, or expanding to look at other non-canonical signalling 
molecules, that may show a causal mechanism behind prostate cancer 
progression and TGF-β superfamily related signalling. The study has 
highlighted the need to further study the TGF-β superfamily as the 
alterations in TGF-β superfamily related signalling may have an 
association with the progression of prostate cancer. 
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Appendix 1: Recipes 
Recipes 
12% Separating Gel:        
Separating gel: Makes 2 gels                                                                 
3.7mL of ddH2O  
4.5 ml of 30 % acrylamide/bis-acrylamide solution                                
2.8 ml of 1.5 M Tris pH 8.8 and mix                                            
112.5 µL of 10% SDS                                                                     
When ready to use, add 11.25 µL of TEMED and mix                                      
Immediately before pouring the gel, add 112.5 µL  of 10% APS and 
mix      
 
4% Stacking Gel:                            
Stacking gel: Makes 2 gels 
4.5 mL of ddH2O                                                                       
1 mL of 30 % acrylamide/bis-acrylamide solution                                 
1.88 mL of 0.5 M Tris pH 6.8 and mix                                                   
75 µL of 10% SDS                                                                     
When ready to use, add 7.5 µL of TEMED and mix                                       
Immediately before pouring the gel, add 75 µL of 10% APS and 





5X Running buffer 
Tris 15 g 
Glycine 72 g 
SDS 5 g 
Made up to 1 L 
 
1X Running buffer  
400 mL of 5X Running buffer 
1600 mL of ddH2O 
 
10X Transfer Buffer 
30.3 g Tris 
144g Glycine 
Made up to 1 L 
 
1X Transfer Buffer  
 
100 mL of Methanol or ethanol 
100 mL of 10X Transfer Buffer 
800 mL of ddH2O 
 
4X Laemmli sample buffer 
Bromophenol blue is added  
FOR 20 ml  
 
2.5 mL of tris HCL from 0.5 M stock pH 6.8 
5mL of Glycerol 
8 mL of SDS from 10% Stock 
4.5 mL of Water 
2X Laemmli sample buffer  
FOR 20 ml 
99 
 
2.5 ml of tris HCL from 0.5 M stock pH 6.8 
5ml of Glycerol 
4 ml of SDS from 10% Stock 
8.5 ml of Water 
4X and 2X aliquoted into 1 mL Eppendorf tube 
1,4 Dithiothreitol (DTT) is added at 54 mg per ml of reducing 
buffer 
 
1X Laemmli sample buffer for blank 
FOR 100 μL 
50 μL 2X Liemi’s buffer 
50 μL ddH2O 






















Appendix 2: Patient details, 260/280 ratio, 260/230 
ratio and RNA concentration 
 












11868 54 5 3+2 2.18 2.22 598.74 
12016 63 5 3+2 1.96 1.84 308.47 
12103 52 5 3+2 2 2 303.22 
12484 66 5 3+2 2.12 1.77 761.5 












11921 69 7 3+4 2.05 1.04 310.8 
12036 58 7 3+4 2.45 2.41 70.54 
12169 54 7 3+4 2.3 2 88.44 
12368 68 7 3+4 2.06 1.98 215.76 
12996 67 9 4>5>3 1.93 1.94 352.1 
13014 69 9 4>3>5 1.99 1.02 246.4 
12524 59 8 3+5 2.14 2.14 202.37 




Appendix 3: Gene list for TGF-β focussed array 
Gene list for RT2  Profiler PCR Array Human TGFb Signalling 
Pathway (PAHS-035) 
Refseq Symbol Description 
NM_001105 ACVR1 Activin A receptor, type I 
NM_001616 ACVR2A Activin A receptor, type IIA 
NM_000020 ACVRL1 Activin A receptor type II-like 1 
NM_000479 AMH Anti-Mullerian hormone 
NM_020547 AMHR2 Anti-Mullerian hormone receptor, type II 
NM_001675 ATF4 
Activating transcription factor 4 
(tax-responsive enhancer element B67) 
NM_012342 BAMBI 
BMP and activin membrane-bound inhibitor homolog 
(Xenopus laevis) 
NM_199173 BGLAP Bone gamma-carboxyglutamate (gla) protein 
NM_006129 BMP1 Bone morphogenetic protein 1 
NM_001200 BMP2 Bone morphogenetic protein 2 
NM_001201 BMP3 Bone morphogenetic protein 3 
NM_130851 BMP4 Bone morphogenetic protein 4 
NM_021073 BMP5 Bone morphogenetic protein 5 
NM_001718 BMP6 Bone morphogenetic protein 6 
NM_001719 BMP7 Bone morphogenetic protein 7 
NM_133468 BMPER BMP binding endothelial regulator 
NM_004329 BMPR1A Bone morphogenetic protein receptor, type IA 
NM_001203 BMPR1B Bone morphogenetic protein receptor, type IB 
NM_001204 BMPR2 
Bone morphogenetic protein receptor, type II 
(serine/threonine kinase) 
NM_000389 CDKN1A Cyclin-dependent kinase inhibitor 1A (p21, Cip1) 
NM_004064 CDKN1B Cyclin-dependent kinase inhibitor 1B (p27, Kip1) 
NM_004936 CDKN2B Cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) 
NM_003741 CHRD Chordin 
NM_000088 COL1A1 Collagen, type I, alpha 1 
NM_000089 COL1A2 Collagen, type I, alpha 2 
NM_001920 DCN Decorin 
102 
NM_004405 DLX2 Distal-less homeobox 2 
NM_001423 EMP1 Epithelial membrane protein 1 
NM_000118 ENG Endoglin 
NM_005252 FOS FBJ murine osteosarcoma viral oncogene homolog 
NM_006350 FST Follistatin 
NM_015675 GADD45B Growth arrest and DNA-damage-inducible, beta 
NM_016204 GDF2 Growth differentiation factor 2 
NM_020634 GDF3 Growth differentiation factor 3 
NM_000557 GDF5 Growth differentiation factor 5 
NM_001001557 GDF6 Growth differentiation factor 6 
NM_182828 GDF7 Growth differentiation factor 7 
NM_173849 GSC Goosecoid homeobox 
NM_014685 HERPUD1 
Homocysteine-inducible, endoplasmic reticulum stress-inducible, 
ubiquitin-like domain member 1 
NM_022740 HIPK2 Homeodomain interacting protein kinase 2 
NM_002165 ID1 
Inhibitor of DNA binding 1, 
dominant negative helix-loop-helix protein 
NM_002166 ID2 
Inhibitor of DNA binding 2, 
dominant negative helix-loop-helix protein 
NM_001550 IFRD1 Interferon-related developmental regulator 1 
NM_000618 IGF1 Insulin-like growth factor 1 (somatomedin C) 
NM_000598 IGFBP3 Insulin-like growth factor binding protein 3 
NM_000600 IL6 Interleukin 6 (interferon, beta 2) 
NM_002191 INHA Inhibin, alpha 
NM_002192 INHBA Inhibin, beta A 
NM_002193 INHBB Inhibin, beta B 
NM_002228 JUN Jun proto-oncogene 
NM_002229 JUNB Jun B proto-oncogene 
NM_020997 LEFTY1 Left-right determination factor 1 
NM_000627 LTBP1 Latent transforming growth factor beta binding protein 1 
NM_000428 LTBP2 Latent transforming growth factor beta binding protein 2 
NM_005241 MECOM MDS1 and EVI1 complex locus 
NM_002467 MYC V-myc myelocytomatosis viral oncogene homolog (avian) 
NM_018055 NODAL Nodal homolog (mouse) 
NM_005450 NOG Noggin 
NM_002608 PDGFB Platelet-derived growth factor beta polypeptide 
NM_002658 PLAU Plasminogen activator, urokinase 
NM_001754 RUNX1 Runt-related transcription factor 1 
103 
NM_000602 SERPINE1 
Serpin peptidase inhibitor, clade E 
(nexin, plasminogen activator inhibitor type 1), member 1 
NM_005900 SMAD1 SMAD family member 1 
NM_005901 SMAD2 SMAD family member 2 
NM_005902 SMAD3 SMAD family member 3 
NM_005359 SMAD4 SMAD family member 4 
NM_005903 SMAD5 SMAD family member 5 
NM_005904 SMAD7 SMAD family member 7 
NM_020429 SMURF1 SMAD specific E3 ubiquitin protein ligase 1 
NM_003107 SOX4 SRY (sex determining region Y)-box 4 
NM_007315 STAT1 Signal transducer and activator of transcription 1, 91kDa 
NM_000660 TGFB1 Transforming growth factor, beta 1 
NM_015927 TGFB1I1 Transforming growth factor beta 1 induced transcript 1 
NM_003238 TGFB2 Transforming growth factor, beta 2 
NM_003239 TGFB3 Transforming growth factor, beta 3 
NM_000358 TGFBI Transforming growth factor, beta-induced, 68kDa 
NM_004612 TGFBR1 Transforming growth factor, beta receptor 1 
NM_003242 TGFBR2 Transforming growth factor, beta receptor II (70/80kDa) 
NM_003243 TGFBR3 Transforming growth factor, beta receptor III 
NM_004257 TGFBRAP1 Transforming growth factor, beta receptor associated protein 1 
NM_003244 TGIF1 TGFB-induced factor homeobox 1 
NM_003246 THBS1 Thrombospondin 1 
NM_003810 TNFSF10 Tumor necrosis factor (ligand) superfamily, member 10 
NM_006022 TSC22D1 TSC22 domain family, member 1 
NM_001101 ACTB Actin, beta 
NM_004048 B2M Beta-2-microglobulin 
NM_002046 GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
NM_000194 HPRT1 Hypoxanthine phosphoribosyltransferase 1 
NM_001002 RPLP0 Ribosomal protein, large, P0 
SA_00105 HGDC Human Genomic DNA Contamination 
SA_00104 RTC Reverse Transcription Control 
SA_00104 RTC Reverse Transcription Control 
SA_00104 RTC Reverse Transcription Control 
SA_00103 PPC Positive PCR Control 
SA_00103 PPC Positive PCR Control 




Appendix 4 TGF-β RT-qPCR results 
High grade prostate cancer tissue (Group 1) compared to low grade 
prostate cancer tissue 
Mean fold regulation of high grade tissue (Group 1) compared to 
low grade tissue (Control) normalised to HPRT1 expression. Up-regulated 
greater than 2 fold are shown in red, greater than 2 fold down-regulated 








ACVR1 1.2333 0.222016 INHBB -1.3566 0.526649 
ACVR2A 1.3115 0.413935 JUN -2.4221 0.165032 
ACVRL1 1.0634 0.786512 JUNB -1.2592 0.789383 
AMH 1.2592 0.522554 LEFTY1 1.2451 0.363523 
AMHR2 1.6906 0.290909 LTBP1 1.6529 0.541629 
ATF4 -1.2048 0.513198 LTBP2 1.1299 0.652427 
BAMBI -1.2669 0.245987 MECOM 1.2322 0.633088 
BGLAP 1.014 0.715548 MYC 1.3229 0.592935 
BMP1 -1.0981 0.891286 NODAL 1.2184 0.48529 
BMP2 -1.5678 0.843045 NOG 1.6344 0.316572 
BMP3 2.0139 0.327498 PDGFB 1.6091 0.34293 
BMP4 1.1933 0.483414 PLAU 2.6712 0.182482 
BMP5 -1.1537 0.927138 RUNX1 -1.1105 0.570804 
BMP6 1.5422 0.570105 SERPINE1 1.8261 0.476436 
BMP7 -2.0403 0.155331 SMAD1 -1.1319 0.997856 
BMPER -2.0759 0.777449 SMAD2 1.0488 0.912474 
BBMPR1
A 
-1.1497 0.718389 SMAD3 -2.114 0.220238 
BMPR1B -1.3613 0.606855 SMAD4 -1.1192 0.509601 
BMPR2 1.0727 0.831582 SMAD5 1.0662 0.68033 
CDKN1A -1.4781 0.920746 SMAD7 1.3996 0.396334 
CDKN1B -1.3287 0.659514 SMURF1 1.1134 0.709528 
CDKN2B 2.6072 0.243026 SOX4 -1.7396 0.223648 
CHRD 1.2494 0.441108 STAT1 -1.2857 0.630575 
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COL1A1 1.9862 0.413473 TGFB1 1.2538 0.498757 
COL1A2 2.3457 0.419398 TGFB1I1 1.4179 0.458423 
DCN 1.2058 0.786492 TGFB2 -1.038 0.707207 
DLX2 1.9419 0.978906 TGFB3 -1.7731 0.572629 
EMP1 -2.1214 0.984514 TGFBI 1.9102 0.3553 
ENG 1.3426 0.590639 TGFBR1 1.1125 0.572871 
FOS -1.5 0.867333 TGFBR2 1.3601 0.5689 







GDF2 1.5289 0.356709 TGIF1 -1.6935 0.086732 
GDF3 1.7608 0.332471 THBS1 -1.1299 0.9276 
GDF5 1.8088 0.257986 TNFSF10 -1.1329 0.901328 
GDF6 1.4794 0.312075 TSC22D1 1.007 0.688601 
GDF7 -1.0087 0.914418 ACTB 1.0811 0.697052 
GSC 3.1005 0.07346 B2M -1.6259 0.685617 
HERPUD
1 
-1.8709 0.307747 GAPDH -1.1964 0.726552 
HIPK2 -3.1904 0.186806 HPRT1 1 0 
ID1 -1.0131 0.784187 RPLP0 1.0802 0.618626 
ID2 -1.0552 0.805608 HGDC 1.5131 0.360714 
IFRD1 -1.1202 0.483354 RTC 1.9102 0.464978 
IGF1 1.0184 0.991818 RTC 2.2288 0.304072 
IGFBP3 1.4302 0.478353 RTC 1.6716 0.428683 
IL6 1.2419 0.551426 PPC 1.7808 0.265193 
INHA 1.5013 0.444864 PPC 1.9152 0.229858 





High grade normal adjacent tissue (Group 1) compared to low grade 
normal adjacent tissue 
Mean fold regulation of high grade tissue (Group 1) compared to 
low grade tissue (Control) normalised to HPRT1 expression. Up-regulated 
greater than 2 fold are shown in red, greater than 2 fold down-regulated 








ACVR1 1.244 0.269228 INHBB -1.0254 0.936083 
ACVR2A 1.211 0.231168 JUN 1.1319 0.7235 
ACVRL1 2.5937 0.149759 JUNB 1.2376 0.509959 
AMH 2.1085 0.348939 LEFTY1 2.6367 0.15131 
AMHR2 2.2211 0.347895 LTBP1 1.5249 0.580585 
ATF4 -1.101 0.508882 LTBP2 1.2658 0.515916 
BAMBI -1.7532 0.240192 MECOM 1.5529 0.313675 
BGLAP -1.0634 0.822197 MYC -1.2006 0.558552 
BMP1 1.858 0.51786 NODAL 2.2855 0.350138 
BMP2 1.1647 0.19475 NOG 1.8839 0.744008 
BMP3 2.5228 0.176544 PDGFB 2.0922 0.380864 
BMP4 1.3402 0.465071 PLAU 1.0552 0.993585 
BMP5 12.1257 0.111007 RUNX1 1.2163 0.656754 




BMP7 1.4603 0.47142 SMAD1 -1.279 0.463196 
BMPER 2.5602 0.251077 SMAD2 -1.1447 0.941816 
BMPR1A 1.1964 0.415064 SMAD3 1.6063 0.381101 
BMPR1B -2.7297 0.063565 SMAD4 -1.5 0.175414 
BMPR2 -1.0148 0.752257 SMAD5 -1.1 0.95257 
CDKN1A 1.413 0.450773 SMAD7 1.1749 0.366522 
CDKN1B -1.1567 0.898961 SMURF1 1.268 0.435982 
CDKN2B 2.7156 0.150265 SOX4 1.7351 0.301232 
CHRD 2.2423 0.221316 STAT1 -1.0009 0.817314 
COL1A1 1.9931 0.93559 TGFB1 1.5502 0.176476 
COL1A2 1.5276 0.456985 TGFB1I1 1.101 0.938673 















DLX2 2.0314 0.401282 TGFB3 1.4704 0.236141 
EMP1 -1.7578 0.637308 TGFBI 1.561 0.414435 
ENG 1.4414 0.555897 TGFBR1 1.0524 0.698855 
FOS 1.0534 0.604599 TGFBR2 1.4679 0.283805 
FST 1.1144 0.561763 TGFBR3 1.2269 0.528117 




GDF2 2.0209 0.337694 TGIF1 -1.0299 0.709439 
GDF3 1.9436 0.344505 THBS1 1.2131 0.810732 
GDF5 2.1343 0.356008 TNFSF10 -1.2301 0.455868 
GDF6 1.9235 0.411208 TSC22D1 -1.1398 0.778674 
GDF7 3.4283 0.116166 ACTB -1.4527 0.909683 
GSC 1.8905 0.406415 B2M -1.0736 0.959331 
HERPUD1 -2.2307 0.021372 GAPDH -1.5342 0.58085 
HIPK2 1.1388 0.381051 HPRT1 1 0 
ID1 2.6072 0.529377 RPLP0 -1.2343 0.268654 
ID2 1.0924 0.778137 HGDC 1.9691 0.407455 
IFRD1 -1.0524 0.98606 RTC 1.7532 0.470074 
IGF1 1.6415 0.180063 RTC 1.4679 0.525079 
IGFBP3 1.7186 0.162149 RTC 2.6095 0.365798 
IL6 1.083 0.455521 PPC 1.6716 0.325679 
INHA 3.3929 0.117188 PPC 1.5355 0.333527 
INHBA 3.0131 0.344278 PPC 1.4402 0.511349 
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Appendix 6: Protein mass, Concentration, and 
composition of aliquots  
Mass of samples, RIPA buffer amount, Protease inhibitor amount and 
protein concentration. 
 
Low grade prostate tumour samples 





11868 0.02 170 1.7 3.75 
12016 0.02 240 2.4 3.79 
12103 0.01 80 0.8 5.84 
MEAN 0.02 163.33 1.63 4.46 
High grade prostate tumour samples 





12524 0.02 160 1.6 2.45 
12929 0.01 140 1.4 2.32 
12996 0.01 80 0.8 4.67 








Low grade prostate tumour samples 




Amount of water 
(μL) 
Reducing buffer per 
well (μL) 
11868 8 8 2 10 
12016 7.92 7.9 2.1 10 
12103 5.14 5.1 4.9 10 
MEAN 7.02 7 3 10 
High grade prostate tumour samples 




Amount of water 
(μL) 
Reducing buffer per 
well (μL) 
12524 12.24 15 0 5 
12929 12.93 15 0 5 
12996 6.42 6.42 3.58 10 
MEAN 10.53 12.14 1.19 6.67 
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Appendix 7: Western blot results 
Western blot results showing the expression level of protein of 
interest, GAPDH expression, expression normalised to GAPDH of low 
grade tissues and high grade tissue. Results are divided by background 
removal methods used, Median with border set to 3mm (Median 3), 
Median with border set to 1mm (Median 1), Average  with border set to 1 
mm (Average1) and User defined. Included are the mean expression, 
standard deviation (sd) and coefficient of variation (CV).  
Normalisation of protein of interest to GAPDH carried out by 
dividing the protein of interest expression in a single lane by the GAPDH 
expression in that same lane. 
Normalisation of GAPDH expression carried out by dividing 
individual GAPDH expression of a sample group by the highest GAPDH 
expression in that same group. 
Coefficient of variation (CV) calculated by dividing standard 


























221220 41288 0.47 0.19 
 
469436 90521 1 0.19 
 
93931 28976 0.20 0.31 
Mean 261529 53595 0.56 0.23 
sd 190970 32566 0.41 0.07 











646698 85951 0.65 0.13 
 
998358 167946 1 0.17 
 
548802 37466 0.55 0.07 
Mean 731286 97121 0.73 0.12 
sd 236414 65954 0.24 0.05 











229581 860919 0.80 3.75 
 
287140 708124 1 2.47 
 
42748 169618 0.15 3.97 
Mean 186490 579554 0.65 3.39 
sd 127767 363142 0.44 0.81 
CV 0.69 0.63 0.69 0.24 
 
GAPDH 






436161 876584 0.62 2.00 
 
698901 832255 1 1.19 
 
304848 947855 0.44 3.11 
Mean 479970 885565 0.69 2.10 
sd 200646 58321 0.29 0.96 













220989 863180 0.76 3.91 
 
289972 706509 1 2.44 
 
42364 120029 0.15 2.83 
Mean 184442 563239 0.64 3.06 
sd 127786 391744 0.44 0.76 
CV 0.69 0.70 0.69 0.25 
 
GAPDH 






433173 856320 0.62 1.98 
 
697377 855766 1 1.22 
 
291468 951714 0.42 3.27 
Mean 474006 887933 0.68 2.16 
sd 206012 55236 0.30 1.03 











275604 961318 0.82 3.45 
 
334639 808523 1 2.41 
 
75847 242647 0.23 3.20 
Mean 228697 670829 0.68 3.03 
sd 135623 378605 0.41 0.55 
CV 0.59 0.56 0.59 0.18 
 
GAPDH 






478860 969163 0.65 2.02 
 
741600 894336 1 1.21 
 
345147 932518 0.47 2.70 
Mean 521869 932006 0.70 1.98 
sd 201696 37416 0.27 0.75 



















378703 119554 1 0.32 
 
293306 70935 0.77 0.24 
 
104046 16574 0.27 0.16 
Mean 258685 69021 0.68 0.24 
sd 140563 51517 0.37 0.08 











149308 1650 0.95 0.01 
 
157588 43423 1 0.28 
 
52274 39034 0.33 0.75 
Mean 119723 28036 0.76 0.34 
sd 58559 22956 0.37 0.37 














378703 115270 1 0.30 
 
296906 70935 0.78 0.24 
 
104046 18002 0.27 0.17 
Mean 259885 68069 0.69 0.24 
sd 141021 48697 0.37 0.07 











151708 1650 0.93 0.01 
 
162388 43423 1 0.27 
 
54674 40054 0.34 0.73 
Mean 122923 28376 0.76 0.34 
sd 59346 23206 0.37 0.37 















358591 112386 1 0.31 
 
296794 72419 0.83 0.24 
 
103358 18940 0.29 0.18 
Mean 252914 67915 0.71 0.25 
sd 133154 46886 0.37 0.07 











146633 2570 0.89 0.02 
 
164238 43465 1 0.26 
 
54062 35174 0.33 0.65 
Mean 121644 27070 0.74 0.31 
sd 59187 21619 0.36 0.32 













425684 159867 1 0.38 
 
330687 108392 0.78 0.33 
 
120489 42607 0.28 0.35 
Mean 292287 103622 0.69 0.35 
sd 156179 58775 0.37 0.02 











196289 23457 0.96 0.12 
 
204569 69456 1 0.34 
 
60855 58649 0.30 0.96 
Mean 153904 50521 0.75 0.47 
sd 80689 24052 0.39 0.44 

















275807 124273 0.65 0.45 
 
422654 75037 1 0.18 
 
168329 28373 0.40 0.17 
Mean 288930 75894 0.68 0.27 
sd 127669 47956 0.30 0.16 











536399 28228 0.51 0.05 
 
1050985 57131 1 0.05 
 
403014 41414 0.38 0.10 
Mean 663466 42258 0.63 0.07 
sd 342164 14470 0.32 0.03 














275807 122449 0.65 0.44 
 
423644 75037 1 0.18 
 
168329 26777 0.40 0.16 
Mean 289260 74754 0.68 0.26 
sd 128188 47837 0.30 0.16 











536399 27430 0.51 0.05 
 
1052185 55535 1 0.05 
 
403644 41414 0.38 0.10 
Mean 664076 41460 0.63 0.07 
sd 342604 14053 0.33 0.03 















271702 112161 0.64 0.41 
 
422999 55667 1 0.13 
 
169057 28345 0.40 0.17 
Mean 287919 65391 0.68 0.24 
sd 127746 42746 0.30 0.15 











534907 22462 0.51 0.04 
 
1051615 49617 1 0.05 
 
403247 40274 0.38 0.10 
Mean 663256 37451 0.63 0.06 
sd 342711 13795 0.33 0.03 













285364 130886 0.66 0.46 
 
430962 107956 1 0.25 
 
175999 41342 0.41 0.23 
Mean 297442 93395 0.69 0.31 
sd 127910 46514 0.30 0.12 











544069 45985 0.51 0.08 
 
1061055 81272 1 0.08 
 
408548 48797 0.39 0.12 
Mean 671224 58684 0.63 0.09 
sd 344337 19612 0.32 0.02 
CV 0.51 0.33 0.51 0.24 
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Total pSMAD3 activation (normalised pSMAD3/ normalised SMAD3) 
divided up by the background removal method with mean. 
Low pSMAD3/SMAD3 




0.70 0.69 0.76 0.82 
 
1.36 1.35 1.85 1.31 
 
0.95 1.10 1.09 1.51 
Mean 1.003 1.04 1.23 1.21 
High pSMAD3/SMAD3 
 




4.76 4.70 2.40 0.71 
 
0.20 0.20 0.18 0.22 
 
0.14 0.14 0.15 0.12 































281608 20863 1 0.07 
 
244654 18558 0.87 0.08 
 
100929 9764 0.36 0.10 
Mean 209064 16395 0.74 0.08 
sd 95452 5857 0.34 0.01 











594482 17214 0.81 0.03 
 
738221 17933 1 0.02 
 
366328 11742 0.50 0.03 
Mean 566344 15630 0.77 0.03 
sd 187536 3386 0.25 0.004 













280096 22063 1 0.08 
 
246670 18558 0.88 0.08 
 
99921 9764 0.36 0.10 
Mean 208896 16795 0.75 0.08 
sd 95843 6336 0.34 0.01 











598514 17214 0.80 0.03 
 
744269 17933 1 0.02 
 
366328 11742 0.49 0.03 
Mean 569704 15630 0.77 0.03 
sd 190611 3386 0.26 0.004 
















277062 20935 1 0.08 
 
242607 17858 0.88 0.07 
 
95417 9396 0.34 0.10 
Mean 205028 16063 0.74 0.08 
sd 96477 5975 0.35 0.01 











588350 16086 0.79 0.03 
 
745351 13409 1 0.02 
 
353802 11262 0.47 0.03 
Mean 562501 13586 0.75 0.03 
sd 197050 2417 0.26 0.01 













283413 21737 1 0.08 
 
246459 20832 0.87 0.08 
 
90638 9401 0.32 0.10 
Mean 206837 17323 0.73 0.09 
sd 102313 6876 0.36 0.01 











592255 16907 0.80 0.03 
 
735994 19882 1 0.03 
 
342933 11435 0.47 0.03 
Mean 557061 16075 0.76 0.03 
sd 198880 4285 0.27 0.003 
















200074 34960 0.42 0.17 
 
473370 98893 1 0.21 
 
104705 59398 0.22 0.57 
Mean 259383 64417 0.55 0.32 
sd 191355 32261 0.40 0.22 











649112 107553 0.66 0.17 
 
980252 189548 1 0.19 
 
513815 73768 0.52 0.14 
Mean 714393 123623 0.73 0.17 
sd 239973 59539 0.25 0.02 













203114 34960 0.43 0.17 
 
475650 93013 1 0.20 
 
104705 59398 0.22 0.57 
Mean 261156 62457 0.55 0.31 
sd 192163 29147 0.40 0.22 











649112 110493 0.66 0.17 
 
980252 182198 1 0.19 
 
526070 73768 0.54 0.14 
Mean 718478 122153 0.73 0.17 
sd 234902 55147 0.24 0.02 
















198507 651022 0.66 3.28 
 
469931 983492 1 2.09 
 
105836 516418 0.53 4.88 
Mean 258091 716977 0.73 3.42 
sd 189220 240420 0.24 1.40 











22510 118578 0.23 5.27 
 
98503 187373 1 1.90 
 
52333 77548 0.53 1.48 
Mean 57782 127833 0.59 2.88 
sd 38288 55494 0.39 2.08 













221220 41288 0.47 0.19 
 
469436 90521 1 0.19 
 
93931 28976 0.20 0.31 
Mean 261529 53595 0.56 0.23 
sd 190970 32566 0.41 0.07 











646698 85951 0.65 0.13 
 
998358 167946 1 0.17 
 
548802 37466 0.55 0.07 
Mean 731286 97121 0.73 0.12 
sd 236414 65953 0.24 0.05 



















2734492 1685872 1 0.62 
 
2443941 1072986 0.89 0.44 
 
659074 1584562 0.24 2.40 
Mean 1945836 1447807 0.71 1.15 
sd 1123798 328533 0.41 1.09 
CV 0.58 0.23 0.58 0.94 
 
GAPDH 






196627 41186 0.78 0.21 
 
48029 15220 0.19 0.32 
 
251017 78026 1 0.31 
Mean 165224 44811 0.66 0.28 
sd 105074 31560 0.42 0.06 
CV 0.64 0.70 0.64 0.21 











 2742412 1685872 1 0.61 
 2455461 1072986 0.89 0.44 
 661234 1585552 0.24 2.40 
Mean 1953036 1448137 0.71 1.15 
sd 1127896 328739 0.41 1.08 
CV 0.58 0.23 0.58 0.94 
 
GAPDH 





 195659 41186 0.78 0.21 
 48029 15220 0.19 0.32 
 251017 78026 1 0.31 
Mean 164902 44811 0.66 0.28 
sd 104931 31560 0.42 0.06 

















2737644 1689216 1 0.62 
 
2454157 1063361 0.90 0.43 
 
662042 1576576 0.24 2.38 
Mean 1951281 1443051 0.71 1.14 
sd 1125475 333610 0.41 1.08 
CV 0.58 0.23 0.58 0.94 
  
GAPDH 






196209 41837 0.78 0.21 
 
46792 15682 0.19 0.34 
 
251452 78026 1 0.31 
Mean 164817 45182 0.66 0.29 
sd 105880 31306 0.42 0.06 













2797012 1729614 1 0.62 
 
2492781 1102868 0.89 0.44 
 
688474 1624344 0.25 2.36 
Mean 1992756 1485609 0.71 1.14 
sd 1139738 335616 0.41 1.06 
CV 0.57 0.23 0.57 0.93 
 
GAPDH 






198164 43669 0.78 0.22 
 
48598 15729 0.19 0.32 
 
254490 80509 1 0.32 
Mean 167084 46635 0.66 0.29 
sd 106407 32492 0.42 0.06 








































BMP3 Western blot with 
Gapdh  reference. 
Marker  (Full-range 
Amersham  Rainbow 
marker  RPN  800E)  in 
lane 1, samples in lanes 
2-4, and blank control in 
lane.  Intensities  for  700 
nm  and  800  nm 
channels  are  2  and  2.5 
respectively.
BMP3  (Green  channel) 
Abcam 71500
Bands:  Double  bands 
between 52 kDa and 38 
kDa
Expected  bands:  Two 
bands at 55 kDa and 16 
kDa
Gapdh  (Red  channel) 
Abcam 9485
Bands: 38 kDa
Expected bands: 40 kDa
!!!!           Low grade                 High grade






















Second scanning of BMP3 
blot at a lower intensity to 
better  see  if  there  was 
defintion between bands
BMP3  Western  blot  with 
Gapdh  reference.  Marker 
(Full-range  Amersham 
Rainbow  marker  RPN 
800E) in lane 1, samples in 
lanes  2-4,  and  blank 
control  in lane.  Intensities 
for  700  nm  and  800  nm 
channels  are  1  and  1.5 
respectively.
BMP3  (Green  channel) 
Abcam 71500
Bands:  Double  bands 
between  52  kDa  and  38 
kDa
Expected  bands:  Two 
bands  at  55  kDa  and  16 
kDa
Bands  measured:  52  kDa 
and  38  kDa,  measurd 
together as a doublet
Gapdh  (Red  channel) 
Abcam 9485
Bands: 38 kDa
Expected bands: 40 kDa
!!!!         Low grade              High grade






















SMAD3  western  blot  with 
Gapdh  reference.  Marker 
(Full-range  Amersham 
Rainbow marker RPN 800E) in 
lane  1,  samples  in  lanes  2-4, 
and  blank  control  in  lane. 
Intensities for 700 nm and 800 
nm  channels  are  2  and  2.5 
respectively.$
SMAD3  (Green  channel) 
Abcam 40854
Bands:  52  kDa,  with  non 
specific at 38 kDa and smears 
between 225 and 76 kDa
Expected bands: 48 kDa
Bands measured: 52 kDa
Gapdh  (Red  channel)  Abcam 
9485 
Bands: 38 kDa
Expected bands: 40 kDa
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pSMAD3  Western  blot  with 
Gapdh  reference.  Marker 
(Full-range  Amersham 
Rainbow marker RPN 800E) 
in  lane  1,  samples  in  lanes 
3-5 for “Low grade” and 2-4 
for “High grade” and blank 
control  in  lane  2  for  “Low 
grade” and lane 5 for “High 
grade”.  Intensities  for  700 
nm and 800 nm channels are 
2 and 2.5 respectively.
Phosphorylated  SMAD3 
(Green  channel)  Abcam 
51451
Bands: 52 kDa
Expected bands: 48 kDa
Gapdh (Red channel) Abcam 
9485
Bands: 38 kDa
Expected bands: 40 kDa
!!!!          Low grade                 High grade





















SMAD4  Western  blot  with 
Gapdh  reference.  Marker 
(Full-range  Amersham 
Rainbow marker RPN 800E) 
in  lane  1,  samples  in  lanes 
2-4,  and  blank  control  in 
lane.  Intensities  for  700  nm 
and 800  nm channels  are  2 
and 2.5 respectively.
SMAD4  (Green  channel) 
Cell Signalling 9515
Bands: Between 76 kDa and 
52 kDa
Expected bands: Between 60 
kDa and 80 kDa
Bands  measured:  large 
bands  between  76  amd  52 
kDa
Gapdh (Red channel) Abcam 
9485 Bands: 38 kDa
Expected bands: 40 kDa
!!!!         Low grade              High grade





















Second scanning of  SMAD4 
at  lower  intensities  to  see 
definition  between  SMAD4 
bands, and reduce signalling 
intensity
SMAD4  Western  blot  with 
Gapdh  reference.  Marker 
(Full-range  Amersham 
Rainbow marker RPN 800E) 
in  lane  1,  samples  in  lanes 
2-4,  and  blank  control  in 
lane.  Intensities  for  700  nm 
and  800  nm  channels  are  1 
and 1.5 respectively.
SMAD4 (Green channel) Cell 
Signalling 9515
Bands: Between 76 kDa and 
52 kDa
Expected bands: Between 60 
kDa and 80 kDa
Gapdh (Red channel) Abcam 
9485
Bands: 38 kDa
Expected bands: 40 kDa
!!!!        Low grade                 High grade





















pSMAD1  Western  blot  with 
Gapdh  reference.  Marker  (Full-
range  Amersham  Rainbow 
marker  RPN  800E)  in  lane  1, 
samples  in  lanes  2-4,  and  blank 
control in lane. Intensities for 700 
nm  and  800  nm  channels  are  2 
and 2.5 respectively.
Phosphrylated  SMAD1  (Green 
channel) Abcam 97689
Bands:  52  kDa,  and  unexpected 
band at 24 kDa
Expected bands: 52 kDa
Bands measured: 52 kDa
Bands measured: At 52 kDa
Gapdh (Red channel) Abcam 9485
Bands: 38 kDa
Expected bands: 40 kDa
!!!!  Low grade            High grade





















pERK1  and  pERK2  Western 
blot  with  Gapdh  reference. 
M a r k e r  ( F u l l - r a n g e 
Amersham Rainbow marker 
RPN 800E) in lane 1, samples 
in  lanes  2-4,  and  blank 
control in lane. Intensities for 
700 nm and 800 nm channels 
are 2 and 2.5 respectively.
Phosphorylated  ERK1  and 
ERK2  (Green  channel) 
Abcam47339
Bands:  52  kDa and 38  kDa, 
with smears between 52 kDa 
and 31kDa
Expected bands: Between 44 
kDa and 42 kDa
Gapdh (Red channel) Abcam 
9485
Bands:  38  kDa  some  faint 
bands ar 52kDa
Expected bands: 40 kDa
Bands measured: 38 kDa
!!!!           Low grade                High grade





















Second scanning of pERK1 
and  pERK  2  at  a  lower 
intensity  to  reduce 
saturation  of  signalling  for 
low gradfe pERK bands
pERK1 and pERK2 Western 
blot  with Gapdh reference. 
M a r k e r  ( F u l l - r a n g e 
Amersham  Rainbow 
marker  RPN 800E)  in  lane 
1, samples in lanes 2-4, and 
blank  control  in  lane. 
Intensities  for  700  nm and 
800 nm channels are 1 and 
1.5 respectively.
Phosphorylated ERK 1 and 
ERK  2  (Green  channel) 
Abcam47339
Bands: 52 kDa and 38 kDa
Expected  bands:  Between 
44 kDa and 42 kDa
Gapdh  (Red  channel) 
Abcam 9485
Bands:  38  kDa  some  non 
distinct bands at 52kDa
Expected bands: 40 kDa
Bands measured: 38 kDa
!!!!           Low grade              High grade




















BM7  Western  blot  with 
Gapdh  reference.  Marker 
(Full-range  Amersham 
Rainbow marker RPN 800E) 
in  lane  1,  samples  in  lanes 
2-4,  and  blank  control  in 
lane.  Intensities  for  700  nm 
and  800  nm  channels  are  2 
and 2.5 respectively.
BMP7  (Green  channel) 
Abcam 93636
Bands: non specific repeitive 
bands  between  76  kDa  and 
17 kDa
Expected bands: 49 kDa
Gapdh (Red channel) Abcam 
9485 
Bands: 38 kDa
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INHBA  Western  blot  with 
Gapdh  reference.  Marker 
(Full-range  Amersham 
Rainbow marker RPN 800E) 
in  lane  1,  samples  in  lanes 
2-4,  and  blank  control  in 
lane.  Intensities  for  700  nm 
and 800  nm channels  are  2 
and 2.5 respectively.
INHBA  (Green  channel) 
Abcam 56057
Bands: n/a
Expected bands: 47 kDa
Gapdh (Red channel) Abcam 
9485
Bands: 38 kDa
Expected bands: 40 kDa
!!!!          Low grade                High grade














SMAD1  Western  blot  with 
Gapdh  reference.  Marker 
(Full-range  Amersham 
Rainbow marker RPN 800E) in 
lane  1,  samples  in  lanes  2-4, 
and  blank  control  in  lane. 
Intensities for 700 nm and 800 
nm  channels  are  2  and  2.5 
respectively.
SMAD1  (Green  channel) 
Abcam 63356
Bands:no  specific  bands, 
smear between 225 kDa and 52 
kDa
Expected bands: 52 kDa
Gapdh  (Red  channel)  Abcam 
9485
Bands: 38 kDa
Expected bands: 40 kDa
!!!!           Low grade                High grade
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